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Observational studies have consistently demonstrated associations between exposure 
to air pollution and increased cardiovascular morbidity and mortality. These 
associations are strongest for fine particulate matter (PM), of which particulates from 
the combustion of fossil fuels are an important component. In Europe, the 
contribution to urban PM from diesel emissions is increasing with the popularity of 
diesel engines for road transport. Despite the strength of the epidemiological 
evidence and the emergence of promising hypotheses, the important constituents and 
biological mechanisms responsible for the cardiovascular effects of air pollution are 
largely unknown.  
 
It is possible that nanoparticulates or soluble components of PM may translocate into 
the bloodstream, resulting in direct effects on the vascular endothelium and 
thrombotic pathways. I investigated the potential for inhaled radiolabelled 
nanoparticulates to translocate into the circulation in man. Using two unique human 
exposure facilities I assessed the effects of exposure to combustion-derived 
particulates in dilute diesel exhaust and concentrated ambient fine and ultrafine 
particles on vascular endothelial, endogenous fibrinolytic and myocardial function in 
healthy volunteers and patients with stable coronary artery disease.  
 
In total, forty-two healthy men and thirty-two patients with stable coronary artery 
disease were exposed to particulates or filtered air for 1-2 hours in a series of double 
blind randomised crossover studies. At levels encountered in an urban environment, 
inhalation of dilute diesel exhaust impaired two important and complementary 
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aspects of vascular function in man: the regulation of vascular tone and endogenous 
fibrinolysis. Vascular dysfunction persisted for up to 24-hours following exposure 
and was associated with an increase in systemic inflammatory cytokines. In patients 
with coronary heart disease exposure to diesel exhaust did not aggravate pre-existing 
vasomotor dysfunction, but did exacerbate exercise-induced myocardial ischemia 
and reduce acute endothelial tissue plasminogen activator release.  
 
In contrast, exposure to concentrated ambient particulates, low in combustion 
component, did not affect vascular function in either healthy volunteers or patients. I 
found little evidence that inhaled radiolabelled nanoparticles translocate into the 
circulation and suggest the adverse vascular effects of combustion derived air 
pollution are mediated primarily by their soluble components rather than by a direct 
interaction between nanoparticles and the vasculature. 
 
My findings have identified ischemic, vascular and thrombotic mechanisms that may 
explain in part the observations that exposure to combustion-derived air pollution is 
associated with adverse cardiovascular events including acute myocardial infarction. 
Ongoing research in this area will provide further insight into the adverse effects of 
PM, with the possibility of targeted interventions, such as the use of retrofit particle 
traps on diesel powered vehicles, to reduce the impact of environmental air pollution 






Abstract         3-4 
Contents         5-8 
Declaration         9 
Acknowledgements        10-12 
Abbreviations         13 
 
CHAPTER 1: Introduction - air pollution and atherothrombosis  14-37 
1.1 Overview 
1.2 Air pollution and cardiovascular risk 
1.3 The role of particulate air pollution 
1.4 Observational studies 
1.5 Human exposure systems 
1.6 Potential mechanisms 
 
1.7 Aims and hypotheses 
 
 
CHAPTER 2: Methodology – human exposures and assessment of vascular, 
fibrinolytic and myocardial function      38-60 
2.1 General 
2.2 Exposures to dilute diesel exhaust  
2.3 Exposures to concentrated ambient particles 
2.4 Exposures to technetium-labelled carbon nanoparticles 
2.5 Assessment of vascular and fibrinolytic function 
2.6 Venous sampling and laboratory assays 
 6 
2.7 Data analysis and statistics 
 
CHAPTER 3: Diesel exhaust inhalation causes vascular dysfunction and impaired 








CHAPTER 4: Persistent endothelial dysfunction in humans after diesel exhaust 








CHAPTER 5: Do inhaled carbon nanoparticles translocate directly into the 
circulation in man?         106-128 
 
5.1 Summary 






CHAPTER 6: Ischemic and thrombotic effects of dilute diesel exhaust inhalation in 







CHAPTER 7: Exposure to concentrated ambient particulate does not impair vascular 







CHAPTER 8:  Conclusions and Future directions    178-190 
8.1 Summary of findings 
8.2 Future directions 
 8 
 
REFERENCES        191-204 
 
APPENDIX         205-207 




This thesis represents research undertaken in the Centre for Cardiovascular Sciences, 
University of Edinburgh, the Department of Cardiology, Royal Infirmary of 
Edinburgh, and the Department of Respiratory and Allergy Medicine, Umeå 
University, Sweden during the period August 2003 to August 2006.  
 
British Heart Foundation Project (03/017/15071) and Programme Grants 
(PG/05/003) sponsored these studies, which were conducted through a successful 
collaboration with the University of Umeå. I was personally involved in all of the 
exposures, vascular assessments and data analysis presented in the thesis. In keeping 
with the nature of collaborative research, assistance with the studies in Sweden was 
gratefully received from my colleagues Dr Håkan Törnqvist and Dr Manuel 
Gonzalez at Umeå University. Dr Mark Miller, Edinburgh University, undertook the 
electron-paramagnetic resonance studies presented in Chapter 4. Assistance was also 
provided in the supervision of the exposures and laboratory assays as acknowledged. 
 
Chapters 1, 3, 4, 5, 6 and 7 have been published in peer-reviewed journals. I have 
copyright permission for inclusion of the printed journal manuscripts within this 
thesis. The thesis has not been accepted in any previous applications for a degree and 
all sources of information have been acknowledged. All studies were undertaken in 
accordance with the regulations of the Regional Ethics Board of Umeå, the Lothian 
Research Ethics Committee and with the Declaration of Helsinki of the World 
Medical Association. The written informed consent of each subject or patient was 
obtained before entry into the study. 




The research was conducted under the direct supervision of Professor David Newby 
(Professor of Cardiology and Consultant Cardiologist) and Dr Nicholas Boon 
(Honorary Reader and Consultant Cardiologist) at the University of Edinburgh. 
Without their vision and personal dedication to this project little of what follows 
would have been possible. I am very grateful for the guidance and inspiration they 
have given me over the last three years, and I am looking forward to continuing to 
work together on this and other projects in the future. I am also indebted to Professor 
Ken Donaldson (Professor of Respiratory Toxicology) who has provided me with 
great support throughout. 
 
I would like to acknowledge the British Heart Foundation for supporting these 
studies through the award of Project (03/017/15071) and Programme Grants 
(PG/05/003). Without their generosity this thesis and the research material presented 
would not have been possible. I am also very grateful to the British Cardiovascular 
Society who, through the award of a Michael Davies Clinical Research Fellowship, 
has been instrumental in allowing me to complete this research and have given me 
the incentive to pursue a career in academia.  
 
I would like to thank all the dedicated staff at the Clinical Research Facility (CRF) at 
the Royal Infirmary of Edinburgh and the Wellcome Trust Clinical Research Facility 
(WTRCRF) at the Western General Hospital who provided invaluable assistance and 
entertainment during the often-intensive study schedules. In particular I would like to 
 11 
acknowledge Sharon Cameron and Finny Paterson at the CRF who have created a 
fantastic environment to conduct clinical research. From the WTCRF Kareen 
Darnley’s dedication and friendship whilst we introduced the vascular techniques to 
Umeå was key to the success of this project. 
 
I have been very fortunate in this project to have the opportunity to work with many 
remarkable people from the University of Umeå and the Dutch National Institute for 
Public Health and the Environment (RIVM). In order to conduct the studies 
presented in this thesis I relocated to Umeå for long and often dark periods of the 
year, and I would like to thank my ‘Swedish family’, Anita, Johannes, Frieda and 
Sanna Lindmark, for making me so welcome. Tack så mycket to Anders Blomberg 
and Thomas Sandström, my Swedish supervisors. Both of you have taught me much 
about the value of teamwork and collaboration in clinical research. I am most 
grateful to my fellow doctoral students Simon Robinson, Hakan Törnqvist, Manuel 
Gonzalez and Stefan Barath for their friendship and help over the last five years. 
Hakan and I in particular have worked very closely on this project, and I am very 
grateful for his insight into the world of Russian poetry, the introduction to downhill 
skiing and for saving my life on more than one occasion!  Tack also to Frida 
Holmström, Annika Johansson, Margot Johansson, and Veronika Sjögren for the 
fantastic language lessons and ficka.  
 
The studies in Edinburgh would not have been possible without the help from 
Flemming Cassee and his dedicated team from the RIVM. I am very grateful for the 
dedication and expertise of Paul Fokkens, Daan Leseman, and John Boere. I am 
 12 
indebted to all the volunteers and patients who generously gave up their time to 
participate in these studies and whose interest in the research was of great 
encouragement. 
 
Most important of all is my wife, Charlie, and my family, of whom I am very proud. 
They have been generous, understanding and supportive throughout. 
 13 
ABBREVIATIONS 
ACE = angiotensin converting enzyme  
AHA = American Heart Association 
ANOVA = analysis of variance 
ATOFMS = aerosol time-of-flight mass spectrometer 
AUC = area under curve 
CAPs = concentrated ambient particles 
CO = carbon monoxide 
COMEAP = Committee of the Medical Effects of Air Pollution 
CPC = condensation particle counter 
CPM = counts per minute 
CRP = C-reactive protein 
DEP = diesel exhaust particles 
EBC = exhaled breath condensate 
EPA = Environmental Protection Agency 
EPR = electron paramagnetic resonance 
ET = endothelin 
FBF = forearm blood flow 
IL = interleukin 
ICAM = inter-cellular adhesion molecules 
MAPCEL = mobile ambient particle concentrator exposure laboratory 
NAAQS = National Ambient Air Quality Standards 
NO = nitric oxide 
NO2 = nitrogen dioxide 
NOx = nitrogen oxides 
PAH = polycyclic aromatic hydrocarbons 
PAI = plasminogen activator inhibitor 
PM = particulate matter 
PM2.5  = particulate matter less than 2.5µm in diameter 
PM10 = particulate matter less than 10µm in diameter 
SEM = standard error of the mean 
SMPS = scanning mobility particle sizer 
SNP = sodium nitroprusside 
SO2 = sulphur dioxide 
SOD = superoxide dismutase 
TEAC = Trolox equivalent antioxidant capacity 
TLC = thin layer chromatography 
TNF-α = tissue necrosis factor alpha 
t-PA = tissue plasminogen activator 
VACES = Versatile ambient concentrator exposure system  





















Published by Mills NL, Törnqvist H, Gonzales M, Robinson SD, Boon NA, 
Blomberg A, Sandstrom T, Newby DE, Donaldson K. Air pollution and 





Observational studies have consistently demonstrated an association between 
exposure to particulate air pollution and increased cardiovascular morbidity and 
mortality. Despite the strength of the epidemiological evidence and the emergence of 
promising hypotheses, the important constituents and biological mechanisms 
responsible for the cardiovascular effects of air pollution are largely unknown. 
Oxidative stress and inflammation are central to both the toxicology of particulate air 
pollution and the pathogenesis of atherothrombosis. It is possible that 
nanoparticulates or soluble components may translocate into the bloodstream, 
resulting in direct effects on atherosclerotic plaque stability, the vascular 
endothelium, platelet function and thrombosis. Research in this area will provide 
insight into the adverse vascular effects of air pollution, with the possibility of 
interventions to reduce the impact of environmental air pollution on cardiovascular 





1.2 AIR POLLUTION AND CARDIOVASCULAR RISK  
 
Evidence accumulated over more than 50 years of epidemiological and clinical 
research has established the adverse effects of air pollution on human health. The 
London smog of December 1952 caused more than 4,000 excess deaths [Ministry of 
Health, 1954], and despite the dramatic decreases in levels of air pollution that have 
been achieved since then, the association between air pollution and cardiorespiratory 
morbidity and mortality persists and has been widely established [Anderson et al, 
1996; Dockery et al, 1993]. The World Health Organisation (WHO) currently 
estimates three million people die each year of air pollution, representing 5% of the 
55 million deaths occurring annually in the world [WHO Statistics].  
 
Short-term increases in air pollution exacerbate existing cardiorespiratory disease 
leading to increased hospital admissions and in some patients, death [Peters et al, 
2001a]. Cardiovascular events are now thought to be responsible for the majority of 
these excess deaths [Pope, 2000]. Recent work from several USA cities indicated 
each 10 µg/m3 elevation in fine particles was associated with a 4%, 6% and 8% 
increase in the risk of all cause, cardiorespiratory and lung cancer mortality 
respectively [Pope et al, 2002]. In Edinburgh, a city with relatively low levels of 
pollution, an increase in particulate matter (PM) of 10 µg/m3 was associated with an 
increase in emergency cardiovascular admissions of 4.8% [Prescott et al, 1998]. 
Exposure to air pollution has been associated with exercise-induced myocardial 
ischaemia in patients with coronary heart disease [Pekkanen et al, 2002] and the 
triggering of acute myocardial infarction [Peters et al, 2001a]. In concordance with 
these short-term effects, the risk of mortality from cardiovascular disease is greater 
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for those living in areas of greater pollution [Dockery et al, 1993; Pope et al, 2002]. 
In the most comprehensive study to date Miller and colleagues estimate that long-
term exposure to air pollution increases the risk of death from cardiovascular disease 
by as much as 76% [Miller et al, 2007]. In the UK the government has estimated that 
around 8,000 excess deaths occur per annum as a result of air pollution. 
 
A recent Scientific Statement by the American Heart Association (AHA) [Brook et 
al, 2004] acknowledges that exposure to air pollution is an important risk factor for 
the development of cardiovascular disease. Whilst it is possible to derive estimates of 
the magnitude of risk associated with a population exposure over many years it is 
difficult to estimate individual risk and therefore most governmental advisory bodies 
do not advocate restricting activity on high air pollution days. However, in the recent 
AHA statement the authors suggest that patients with cardiovascular risk factors or 
existing disease should curtail physical activity when air pollution levels exceed Air 
Quality Standards. Perhaps a surprising statement, given at the time of writing there 
had been no published studies to assess the direct effects of air pollutants on patients 
with ischaemic heart disease. The Committee on the Medical Effects of Air Pollution 
(COMEAP) who advise the Department of Health in the UK have recently reviewed 
the literature and concluded that patients should not avoid exercise on the grounds 
that this will reduce their exposure to air pollutants as the value of exercise in 
preventing heart disease is likely to be more important [Committee on the Medical 
Effects of Air Pollution, 2006].  
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Both COMEAP and the AHA Expert Panel agree that a better understanding of the 
components and mechanisms responsible for the association between air pollution 
and cardiovascular disease is urgently needed. 
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1.3 THE ROLE OF PARTICULATE AIR POLLUTION 
 
Air pollutants implicated as potentially harmful include particles, nitrogen dioxide, 
ozone, sulphur dioxide and volatile organic compounds and the particles appear to be 
the most harmful component of the pollution ‘cocktail’. Large particles are mostly 
derived from soil and crustal elements whereas fine particles are primarily produced 
from the combustion of fossil fuels by motor vehicles or in power generation. Both 
the WHO and United Nations have declared that the most significant global air 
pollution threat is posed by PM. Of these, only small particles can be inhaled into the 
lungs and national air standards have been based on the mass concentration of such 
‘inhalable’ particles, typically defined as having an aerodynamic diameter centred 
around 10 µm (PM10). In the world's twenty largest cities, peak concentrations of 
PM10 may exceed 1000 µg/m
3, with average levels in the range 200-600 µg/m3 and 
only three of these cities have levels of PM pollution within current guidelines 
[WHO Report, 1994].  
 
The individual components of PM10 are not especially toxic at ambient levels and 
some that contribute a large part of the mass, e.g. salt crystals, are harmless. 
Therefore toxicologists generally consider that one or more components of PM10 
mediate the adverse health effects. The main components considered likely initiators 
of inflammation leading to the adverse effects of PM10 are combustion-derived 
nanoparticles, transition metals, and polycyclic aromatic hydrocarbons (PAH). 
 
Pope et al demonstrated the risk of adverse effects associated with PM2.5 (particles 
<2.5µm in aerodynamic diameter) was greater than for PM10 [Pope et al, 2002] and 
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toxicological studies have emphasised the increased toxicity of the smaller size 
fractions [reviewed in Donaldson et al, 2000; Donaldson et al, 2001]. PM10 contains 
a variable ultrafine component that is greatest near automotive sources. Diesel soot is 
an example of a carbon-centred combustion-derived particle that is ultrafine in terms 
of primary particle size [Tobias et al, 2001]. It has been hypothesised that ultrafine 
particles show more free radical oxidant capacity than non-ultrafine particles 
suggestive of a greater direct oxidative stress at the particle surface [Li et al, 1999]. 
Thus the toxicity of particulate matter appears to relate to the number of particles 
encountered, their size or surface area, and their chemical composition [MacNee and 
Donaldson, 2000]. The very small particles (<50 nm) derived directly from 
combustion sources aggregate readily into larger aggregates, ranging from nanometre 
size up to a micrometer. It is unclear if these aggregates of ultrafine particles in 
PM10, although not ultrafine by aerodynamic size, maintain the toxicity of their 
ultrafine components. However, in toxicological studies, aggregates of such particles 
cause lung responses consistent with their surface area predicted from the ultrafine 





1.4 OBSERVATIONAL STUDIES 
 
 
The cardiovascular morbidity and mortality associated with increases in PM are well 
documented [reviewed in Brook et al, 2003; Brook et al, 2004; Routledge et al, 
2003]. Temporal variations in PM are utilised by ‘time series’ studies to relate the 
moving average to defined end-points such as hospital admissions for ischaemic 
heart disease or cardiovascular deaths. Using this approach there is a clear 
relationship between PM10 and cardiovascular events in the days following an 
increase in the levels of particulate (Table 1.1).  
 
Table 1.1. Percentage change in cardiovascular outcomes per 10g/m3 increase in 
PM10 (Adapted from the COMEAP Report, 2006) 
 




Cardiovascular mortality 0.5 (0.4-0.7) 
Cardiovascular admissions 0.5 (0.2-0.7) 
Ischaemic heart disease admissions 0.8 (0.6-0.9) 
 
The composition of urban PM is dependent on local sources, with concentrations 
dependent on a number of variables including distance from source, wind speed and 
direction. This spatial dimension is utilised in environmental studies where 
populations living in areas of high air pollution are compared to those in areas with 
low air pollution. A good example of this type of study is the Harvard 6 cities study, 
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where cardiovascular disease was more prevalent in areas with the highest PM levels 
(Table 1.2).  
 
Table 1.2. Adjusted mortality rate ratios for the most versus the least polluted city in 
the US 6-cities study (Adapted from the COMEAP Report, 2006) 
 
Outcome Most versus least polluted city 
All mortality 1.26 (1.08-1.47) 
Mortality due to cardiopulmonary disease 1.37 (1.11-1.68) 
 
More detailed information, helpful in understanding the likely mechanisms 
responsible for the cardiovascular effects of PM, has been provided by panel studies. 
These studies relate changes in physiological endpoints to temporal changes in PM 
air pollution in susceptible cohorts. Elevations in PM have been associated with 
increases in heart rate [Peters et al, 1999], decreased heart rate variability [Gold et al, 
2000], and systemic vascular dysfunction [O'Neill et al, 2005]. Further discussion of 
these observational studies can be found in the following useful and detailed reviews 
of the epidemiological literature [Pope, 2000; Brunekreef and Holgate, 2002].   
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1.5 HUMAN EXPOSURES SYSTEMS  
 
Epidemiological studies cannot prove a causative biological effect of air pollution 
exposure. Assessing individual human exposure to particles using data from local 
area monitoring systems may be inaccurate as it is known that personal exposures 
may be several times higher than corresponding area measurements [Watt et al, 
1995]. Systems designed to deliver controlled amounts of air pollution now exist to 
allow a mechanistic approach to determining the effect of inhaled PM. These include 
concentrated ambient particles (CAPs) within filtered air [Ghio et al, 2000] or 
controlled delivery of diesel exhaust particles [Nightingale et al, 2000; Salvi et al, 
1999]. 
 
There are significant differences in the chemical composition and size distribution of 
PM at various distances from a road because of a wide range of sources, 
meteorological conditions, atmospheric chemistry, and temporal factors. The 
development of PM concentrators has fundamentally changed research into the 
causal factors associated with exposure to PM. The concentrators are capable of 
concentrating particles up to 30 times ambient concentrations thereby facilitating 
toxicological studies which were previously impossible, and allowing researchers to 
accurately quantify dose-response relationships following PM exposure. 
 
Because of the hypothesis that combustion-derived particles are important, studies 
utilising diesel exhaust remain crucial in determining the health effects of exposure 
to the combustion-derived component of air pollution [Nightingale et al, 2000; 
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Rudell et al, 1994]. Compared with petrol engines, diesel engines produce less 
carbon monoxide but more nitrogen oxides and aldehydes. They also generate an 
ultrafine singlet particulate that is carbon-centred, and polycyclic aromatic 
hydrocarbon, metal and sulphate-rich [Scheepers and Bos, 1992]. These rapidly 
aggregate and are thought to be one of the key components that mediate the observed 
adverse health effects of PM10 [Schwartz et al, 1996]. The particulate emission from 
diesel engines is over 100 times higher than the particulate emission from an 
equivalent petrol engine with a catalytic converter [Sydbom et al, 2001]. Over 80% 
of diesel exhaust particles have a size of <0.1 µm, and these represent a substantial 
component of the PM10 fraction. By way of their larger surface area, these submicron 
particles may carry a large fraction of toxic compounds on their surface [Levsen, 
2002]. They are deposited deep within the lung with high efficiency from where they 
are only slowly cleared leading to a prolonged time period over which they might 
exert harmful effects.  
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1.6 POTENTIAL MECHANSIMS  
 
 
A number of interesting theories have been proposed to explain the association 
between increased PM and cardiovascular disease. Based on our existing knowledge, 
we present a summary of the potential pathways linking inhaled particles to 
atherothrombosis and adverse cardiovascular outcomes in Figure 1.1. According to 
this model, inhaled particles cause pulmonary and systemic inflammation that 
indirectly impacts on the cardiovascular system. Smaller particles may also 
translocate into the bloodstream exerting direct effects on the vasculature. Once in 
the circulation particles could affect thrombogenesis through endothelial cell or 
platelet activation, or may penetrate the vessel wall, promoting atherosclerosis or 





Figure 1.1  Hypothetical pathways linking inhaled particles to the pathogenesis of 
atherothrombosis and acute cardiovascular events. 
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1.6.1  Pulmonary and Systemic Inflammation 
In vitro studies, animal models and human exposures have clearly established that 
particles exert their pathogenic effects primarily through oxidative stress and 
inflammation [Donaldson and Tran, 2002]. PM10 particles cause lung inflammation 
in animal models following intra-pulmonary instillation [Li et al, 1996] and 
inhalation of roadside ambient particles [Elder et al, 2004a]. In human studies 
inflammatory effects have been demonstrated following inhalation of CAPs [Ghio et 
al, 2000; Holgate et al, 2003] and dilute diesel exhaust [Salvi et al, 1999; Salvi et al, 
2000]. 
 
Increases in plasma or serum markers of systemic inflammation have been reported 
following exposure to particles. In panel and population studies PM exposure is 
associated with evidence of an acute phase response with increased C-reactive 
protein (CRP) [Peters et al, 2001b] and plasma fibrinogen [Pekkanen et al, 2000; 
Schwartz, 2001], enhanced plasma viscosity [Peters et al, 1997] and altered 
haematological indices [Seaton et al, 1999]. In animal studies there are similar 
reports with increased fibrinogen in the blood of PM-exposed hypertensive rats 
[Cassee et al, 2002] and normal rats exposed to ultrafine carbon particles [Elder et al, 
2004b]. In a recent clinical study inhalation of carbon ultrafine particles altered 
leukocyte expression of adhesion molecules in peripheral blood suggesting a 
systemic inflammatory response [Frampton et al, 2006].  
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1.6.2  Vascular inflammation, atherosclerosis and plaque stability 
Atherosclerosis was initially considered a disorder of lipid storage and metabolism, 
but in recent years evidence has emerged to suggest it is caused by a dynamic 
inflammatory process of which endothelial dysfunction is one of the earliest features 
[Ross, 1999]. Endothelial activation results in the upregulation of leukocyte adhesion 
proteins and initiates local vascular inflammation. The release of growth factors and 
pro-inflammatory cytokines results in leukocyte and monocyte recruitment, induction 
of atheroma formation and further arterial damage. Plaque expansion and disruption 
can lead to angina and acute coronary syndromes, including myocardial infarction 
[Blum and Miller, 1996; Ross, 1999]. 
 
Patients with overt cardiovascular disease [Haverkate et al, 1997] and those with 
cardiovascular risk factors have increased biomarkers of systemic inflammation [Lee 
and Libby, 1997]. Increased plasma CRP concentrations have been shown to predict 
the risk of acute myocardial or cerebral infarction independent of other risk factors 
[Ridker and Haughie, 1998; Ridker et al, 2000]. Experimental studies suggest that 
CRP is not just a biomarker of atherosclerosis, but may have effects on endothelial 
cell function and may have a direct role in the pathogenesis of atherosclerosis 
[Verma and Yeh, 2003]. Clinical studies using Salmonella typhus vaccination as a 
model of acute systemic inflammation demonstrate that inflammation can transiently 
but profoundly alter systemic endothelial function [Hingorani et al, 2000]. Indeed, 
patients with chronic systemic inflammation, such as rheumatoid arthritis, have 
evidence of significant endothelial dysfunction [Bergholm et al, 2002] and 
accelerated atherosclerosis [Roman et al, 2006]. 
 29 
 
Systemic inflammation follows short-term exposure to increased levels of PM10, with 
changes in white blood cell and platelet numbers [Ruckerl et al, 2007b], interleukin-
6 (IL-6) [Ruckerl et al, 2007a], CRP [Pope, 2001; Ruckerl et al, 2006] and 
fibrinogen concentrations [Pekkanen et al, 2000; Schwartz, 2001], enhanced plasma 
viscosity [Peters et al, 1997] and altered in coagulation Factor VII concentration 
[Seaton et al, 1999]. Experimental exposures confirm these clinical findings [van 
Eeden et al, 2001] and demonstrate direct evidence of systemic inflammation [Salvi 
et al, 1999] and endothelial dysfunction [Vincent et al, 2001; Sun et al, 2005a]. 
 
It is plausible that repeated exposure to PM might induce the vascular inflammation 
of atherosclerosis and promote plaque expansion or rupture. The first direct evidence 
to support this hypothesis was provided by Suwa and co-workers [Suwa et al, 2002] 
who demonstrated that instillation of high doses of PM10 resulted in plaque 
progression and destabilization in an animal model of atherosclerosis. In the same 
studies PM10 exposure accelerated monocyte release from the bone marrow [Goto et 
al, 2004]. The amount of particulate phagocytosed by alveolar macrophage 
correlated with both the bone marrow response and plaque volume [Goto et al, 2004] 
suggesting a role for pulmonary inflammation and systemic mediators in determining 
the proatherogenic effects of PM. In Apolipoprotein E knock out mice, inhalation 
exposure to ultrafine PM for 6 months increased atherosclerotic plaque volume, 
altered plaque composition and upregulated vascular inflammation [Chen and 
Nadziejko, 2005; Sun et al, 2005a]. These changes in plaque morphology were 
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accompanied by abnormal vascular function characterised by exaggerated 
vasoconstriction and impaired endothelial dependent vasodilatation [Sun et al, 2005].   
 
A recent panel study in Los Angeles provided the first evidence of a link between 
chronic PM exposure and atherosclerosis in man [Kunzli et al, 2005]. A 10 g/m3 
increase in PM2.5 was associated with an increase in carotid intima-media thickness, 
an ultrasonic measure of atheroma, suggesting that long-term ambient PM exposure 
may affect the development of atherosclerosis in man. These data together suggest 
that PM-induced pulmonary inflammation is capable of systemic effects, which can 
contribute to the progression of atherosclerosis.  
 
1.6.3 Endothelial vasomotor function and endogenous fibrinolysis 
In health the vascular endothelium delicately balances regulatory pathways 
controlling blood flow, coagulation, fibrinolysis and inflammation. It is widely 
recognized that a variety of risk factors including cigarette smoking can influence 
vascular tone through endothelium-dependent actions, and there is now extensive 
evidence of abnormal endothelium-dependent vasomotion in patients with 
atherosclerosis [Celermajer et al, 1996; Ludmer et al, 1986; Newby et al, 1999]. As 
combustion products and particulate matter are common to both air pollution and 
cigarette smoke, we hypothesised that air pollution is likely to have similar 
detrimental effects on vascular function.   
 
Whilst nitric oxide (NO) dependent vasomotion is important, it may not be 
representative of other aspects of endothelial function, such as the regulation of 
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fibrinolysis. Small areas of endothelial denudation and thrombus deposition are a 
common finding on the surface of atheromatous plaques and are usually sub-clinical. 
Endogenous fibrinolysis and ‘passification’ of the lesion may therefore be able to 
prevent thrombus propagation and vessel occlusion [Davies, 2000]. However, in the 
presence of an adverse pro-inflammatory state or an imbalance in the fibrinolytic 
system, such microthrombi may propagate, ultimately leading to arterial occlusion 
and tissue infarction [Rosenberg and Aird, 1999]. Thus, the initiation, modification 
and resolution of unstable and inflamed atheromatous plaques may be critically 
dependent on the cellular activation and function of the surrounding endothelium and 
vascular wall. 
 
The fibrinolytic factor tissue plasminogen activator (t-PA) regulates the degradation 
of intravascular fibrin and is released from the endothelium through the translocation 
of a dynamic intracellular storage pool [van den Eijnden-Schrauwen et al, 1995]. If 
endogenous fibrinolysis is to be effective, then the rapid mobilisation of t-PA from 
the endothelium is essential because thrombus dissolution is much more effective if 
t-PA is incorporated during, rather than after, thrombus formation [Fox et al, 1985]. 
The efficacy of plasminogen activation and fibrin degradation is further determined 
by the relative balance between the acute local release of t-PA and its subsequent 
inhibition through formation of complexes with plasminogen activator inhibitor type 
1 (PAI-1). This dynamic aspect of endothelial function and fibrinolytic balance may 





1.6.4 Direct effects of translocated particles on the endothelium and platelets 
The nanoparticle component of inhaled PM may influence the cardiovascular system 
through indirect effects mediated by pulmonary inflammation or through the direct 
action of particles that have become blood-borne. Translocation of inhaled 
nanoparticles across the alveolar-blood barrier has been demonstrated in animal 
studies for a range of nanoparticles delivered by inhalation and instillation [Nemmar 
et al, 2002; Nemmar et al, 2001; Kreyling et al, 2002; Oberdorster et al, 2002]. 
Whether inhaled nanoparticulate can readily access the circulation in humans is 
controversial and is the subject of intense research debate. 
 
Once circulating, nanoparticles may interact with the vascular endothelium, or have 
direct effects on atherosclerotic plaques causing local oxidative stress and pro-
inflammatory effects similar to those found in the lungs. Increased inflammation 
could destabilize the coronary plaque, resulting in rupture, thrombosis and an acute 
coronary syndrome. Certainly, injured arteries can take up blood borne nanoparticles 
[Guzman et al, 1996], a fact exploited by the nanotechnology industry for both 
diagnostic and therapeutic purposes in cardiovascular medicine. The intra-arterial 
infusion of carbon black nanoparticles has a detrimental effect on the mouse 
microcirculation with upregulation of von Willebrand factor expression and 
enhanced fibrin deposition on the endothelial surface [Khandoga et al, 2004].  These 
prothrombotic effects are in keeping with toxicological evidence from inhalation 
studies, which suggest particle exposure may promote thrombogenesis [Nemmar et 
al, 2003a; Nemmar et al, 2003b]. 
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Direct effects of particles on endothelial cells 
Blood-borne particles could interact directly with vascular endothelial cells. The 
direct effects of PM on the expression of genes related to thrombogenesis and 
fibrinolysis has been studied in cultured endothelial cells [Gilmour et al, 2005]. PM10 
caused a direct, dose dependent and sustained impairment in endothelial cell 
production of t-PA. Impaired acute t-PA release in the event of intravascular 
thrombus formation would cause an imbalance between pro-fibrinolytic factors and 
their endogenous inhibitors preventing thrombus dissolution. Additionally, PM10 
caused a concomitant up-regulation of endothelial tissue factor expression, a potent 
stimulus for thrombus formation. Taken together these observations suggest that 
PM10 promotes thrombogenesis in particle-exposed endothelium via two distinct but 
related pathways: enhanced endothelial tissue factor expression and impaired t-PA 
release. 
Direct effects of particles on platelets 
Platelets are numerous in the bloodstream and are central to the process of 
intravascular thrombus formation. Few studies have addressed the direct effects of 
particles on platelets. In the experimental studies of Nemmar [Nemmar et al, 2003a; 
Nemmar et al, 2003b] in vivo thrombosis is induced by endothelial injury using the 
Rose-Bengal model. In hamsters treated with intra-tracheal diesel particles, both 
arterial and venous thrombosis was increased in a dose dependent manner. Platelets 
sampled from the instilled animals underwent more aggregation in vitro, although it 
is unclear whether enhanced in vivo thrombus formation was due to inflammation or 
the direct effects of the particles on platelet function. However, platelets isolated 
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from normal hamsters and treated with diesel exhaust particles (DEP) showed 
increased aggregation, suggesting that direct effects were at least plausible.   
 
In a more comprehensive study [Radomski et al, 2005], a range of manufactured 
nanoparticles including carbon nanotubes, fullerenes, urban PM and carbon 
nanoparticles were incubated with platelets in vitro. Platelet aggregation was 
assessed and clear differences in the potency of these particles were evident. 
Fullerenes were without effect, urban dust and multi-walled nanotubes caused 
modest aggregation, whilst mixed carbon nanoparticles and single walled nanotubes 
were highly potent activators of platelets upregulating platelet glycoprotein IIb/IIIa 
receptor expression and enhancing aggregate formation. In a ferric chloride induced 
rat carotid artery thrombosis model, a similar potency was observed with particles 
enhancing the rate of thrombus formation. Unfortunately, there was little 
characterization of these particles that might have allowed features such as surface 
area or chemistry to be linked to the variation in effect on platelet aggregation or 
thrombus formation.  
 
1.6.5 Arrhythmogenesis 
Whilst arrhythmias are unlikely to account for many of the manifestations of the 
adverse cardiovascular effects of air pollution, they may be implicated in 
hospitalisation for cardiovascular disease and the incidence of sudden cardiac death. 
Most studies to date have addressed this issue by examining effects on heart rate 
variability due to its association with an increased risk of cardiovascular morbidity 
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and mortality in both healthy individuals [Tsuji et al, 1996] and survivors of 
myocardial infarction [Kleiger et al, 1987]. 
 
Liao and colleagues were the first to report an association between PM2.5 and heart 
rate variability in a panel of elderly subjects [Liao et al, 1999]. The authors 
considered their finding somewhat exploratory, but the analysis revealed an inverse 
correlation between same day PM2.5 concentrations and both the high and low 
frequency power domains. They hypothesize that an effect of PM exposure on the 
autonomic control of heart rate and rhythm may explain the association between PM 
and adverse cardiovascular outcomes. Subsequently numerous panel studies have 
explored this mechanistic hypothesis by studying the associations between levels of 
different air pollutants and changes in heart rate variability or incidence of cardiac 
arrhythmia. Whilst controlled exposure studies to ultrafine carbon particles and 
sulphur dioxide have attempted to bring clarity [Routledge et al, 2006], the current 
literature is inconsistent in the magnitude, type and direction of these changes, 
making firm conclusions challenging.  
 
Direct evidence that air pollution may be a trigger for arrhythmia has been further 
assessed in studies of high-risk patients with implanted cardiac defibrillators (ICDs). 
In a pilot study, estimated community acquired exposures to fine particulate and 
other traffic-derived air pollutants were associated with an increase in the number of 
defibrillator interventions amongst 100 patients with ICDs [Peters et al, 2000]. 
However, in a larger more complete analysis with longer follow up, there was no 
increase in the risk of ventricular arrhythmia unless the analysis was restricted only 
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to those patients requiring frequent ICD interventions [Dockery et al, 2005]. It 
should also be recognised that acute myocardial ischaemia secondary to an acute 
coronary syndrome is the most common trigger for life threatening arrhythmias. 
Overall, the pro-arrhythmic potential of air pollution remains uncertain and has yet to 
be definitively established. 
 
1.6.6 Summary 
Recent experimental studies suggest multiple plausible mechanistic pathways 
whereby particles may exert adverse effects on the cardiovascular system. Systemic 
inflammation and endothelial dysfunction are central to this hypothesis. Particles or 
soluble components may translocate into the bloodstream, resulting in direct effects 
on atherosclerotic plaque stability, the vascular endothelium, platelet function and 
thrombosis. Whether these pathways are relevant in man and underpin the 
association between air pollution and acute cardiovascular events is at present 
unclear. 
 
1.7 AIMS AND HYPOTHESES 
 
 
The principle aim of this thesis is to derive a better understanding of the biological 
mechanisms whereby inhaled air pollutants influence the cardiovascular system.   
Specifically we aim to determine the effects of exposure to diesel exhaust and CAPs 
on vascular and fibrinolytic function in man. Furthermore we hope to establish 
whether patients with coronary heart disease are more susceptible to the effects of air 
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pollution. We will explore the role of oxidative stress, inflammation and systemic 
translocation in determining the vascular effects of these exposures. 
 
Appreciation of the effects of air pollution on the cardiovascular system may have 
implications in the future prevention, treatment and management of patients with 
coronary heart disease. Identifying the harmful constituents of urban air pollution 
would allow a more targeted approach in future environmental health policies to 
reduce the adverse effects of air pollution on our health. 
 
The following hypothesis will be addressed: 
 
1. Exposure to dilute diesel exhaust causes an acute impairment of endothelial 
vasomotor and fibrinolytic function in healthy volunteers (Chapter 3) 
2. Vascular dysfunction following exposure to diesel exhaust is due to oxidative 
stress and systemic inflammation (Chapter 4)  
3.  Inhaled radiolabelled nanoparticles can translocate from the lung into the 
circulation in healthy volunteers (Chapter 5)  
4. Patients with coronary heart disease are more susceptible to the adverse 
vascular effects of diesel exhaust (Chapter 6) 
5.  Exposure to concentrated ambient fine and ultrafine particles will similarly 
impair vascular and fibrinolytic function in patients with coronary heart 






METHODOLOGY – HUMAN EXPOSURES AND ASSESSMENTS OF 








2.1.1 Subject Recruitment 
Healthy Volunteers 
Healthy male non-smoking volunteers (aged between 18 and 70 years) were recruited 
by way of local advertisement or from a volunteer database held at the University of 
Umeå. An information sheet was sent to suitable volunteers who fulfilled the 
inclusion/exclusion criteria outlined below. Participating subjects General 
Practitioners were informed in writing. 
 
Subjects taking regular medication and those with clinical evidence of atherosclerotic 
vascular disease, arrhythmia, diabetes mellitus, hypertension (systolic blood pressure 
>150 mmHg), renal or hepatic failure, asthma, significant occupational exposure to 
air pollution, or an inter-current illness likely to be associated with inflammation 
were excluded from the study. Subjects had normal lung function and reported no 
symptoms of respiratory tract infection for at least six weeks prior to or during the 
study. 
 
Patients with Coronary Heart Disease 
Potential subjects were identified from databases of patients who had undergone 
coronary angiography within the Royal Infirmary of Edinburgh or University 
Hospital Umeå. A study information sheet was posted to suitable subjects meeting 
study inclusion/exclusion criteria defined below. The General Practitioner and 
Consultant Cardiologist responsible for participating subjects care were informed. 
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All patients had proven coronary heart disease with a previous myocardial infarction 
(>6 months previously) or had confirmed coronary artery disease on angiography, 
and were receiving standard secondary preventative therapy. Patients with angina 
pectoris (Canadian Cardiovascular Society grade 2), a history of arrhythmia, 
diabetes mellitus, uncontrolled hypertension, renal or hepatic failure, or those with 
unstable coronary disease (acute coronary syndrome or unstable symptoms within 3 
months) were excluded. All volunteers were invited to a pre-study screening visit for 
exercise stress testing and patients unable to achieve stage 2 of the Bruce protocol, or 
patients who had marked ECG changes (left bundle branch block, early ST 
depression >2mm) or developed hypotension were excluded. Current smokers and 
those with asthma, significant occupational exposure to air pollution, or an inter-
current illness were also excluded from the study.  
 
2.1.2 Ethical Considerations 
All studies were undertaken in accordance with the regulations of the Lothian 
Research Ethics Committee, Umeå Regional Ethical Review Board, and with the 
Declaration of Helsinki of the World Medical Association. The written informed 
consent of each subject or patient was obtained before entry into the study. Further 
details of the ethical review process are available on www.clinicaltrials.gov 
(reference number NCT00437138). 
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2.1.3 Subject Preparation 
Subjects were requested to abstain from alcohol for 24 hours and food, caffeine-
containing drinks and tobacco for at least 4 hours before each study. All medication 
was continued throughout the study period, with the exception of angiotensin 
converting enzyme (ACE) inhibitors, which were withdrawn 7 days prior to each 
vascular study as it augments bradykinin induced endothelial t-PA release [Witherow 
et al, 2002]. All studies were conducted in a quiet temperature-controlled room 
maintained at 22-25oC. 
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2.2 EXPOSURES TO DILUTE DIESEL EXHAUST 
 
Controlled exposures to dilute diesel exhaust in healthy volunteers and patients with 
coronary heart disease were performed using a unique and well-characterised 
exposure facility in Umeå, Sweden. This exposure facility has been used to study the 
effects of dilute diesel exhaust on lung inflammation and function in a range of 
healthy volunteers and patients with pulmonary disease since its inception in 1994. 
The exposures are standardised to ensure a particle concentration of 300 g/m3. 
These concentrations are found on a regular basis in heavy traffic, occupational 
settings, and in the world’s most-polluted cities. 
 
2.2.1 Diesel exhaust exposure and monitoring  
The diesel exhaust was generated from an idling Volvo diesel engine (Volvo TD45, 
4.5L, 4 cylinders, 680rpm) from Swedish Low Sulphur Gasoil E10 (Preem, 
Göteborg, Sweden). Over 90% of the exhaust was shunted away, and the remainder 
diluted with filtered air heated to 20oC (humidity ~50%) before being fed into a 






























Figure 2.1 (a) Idling diesel engine and (b) whole body exposure chamber for human 
exposure studies to dilute diesel exhaust. 
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The chamber was continuously monitored for pollutants with exposures standardised 
using real time measurements of nitrogen oxides (NOx) to deliver a particulate matter 
(PM) concentration of 300 µg/m3. Nitrogen dioxide (NO2) and nitrogen oxide (NO) 
were measured online using a chemiluminescence technique (ECO Physics CLD 700 
AL Med, Switzerland). A UNOR 610 infrared spectrophotometer (Maihak AG, 
Hamburg, Germany) was used for online monitoring of carbon monoxide (CO). 
Total hydrocarbon in the exposure aerosol was measured using a flame ionization 
detection method (Hydrocarbon Analyzer, Model 3-300, JUM Engineering Co, 
Oakland, California, USA). Continuous registration of the number of particles <1 m 
diameter/cm3 was obtained with a condensation particle counter (CPC) (TSI, St Paul, 
MN, USA). The size distribution of particulate in the exposure chamber was 
determined by a scanning mobility particle sizer (SMPS) (TSI, Inc., Shoreview, MN, 
USA). 
 
There was little variation in particle number (1.26 ±0.01 particles/cm3), NOx 
(4.45±0.02 parts per million, ppm), NO2 (1.01±0.01 ppm), NO (3.45±0.03 ppm), CO 
(2.9±0.1 ppm) and total hydrocarbon (2.8±0.1 ppm) concentrations between 
exposures. The size distribution of PM in the exposure chamber showed a lognormal 
distribution, typically ranged from 20 to 120 nm, with a count median diameter of 54 
nm (geometric standard deviation = 1.7 nm; Figure 2.2). The polycyclic aromatic 
hydrocarbons (PAHs) consisted of semi-volatile gaseous compounds with only a 
minor fraction (3.5%) present as particulate associated material, 0.04% of total PM 
and 0.06% of the PM organic fraction. The dominating PAHs were phenanthrene, 
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fluorene, 2-methylfluorene, dibenzothiophene and different methyl-substituted 



















Figure 2.2 a) Particle number () and count median diameter () of particulate 
during controlled exposure to dilute diesel exhaust for 60 minutes (mean±SEM, 
n=5). b) The size of inhaled diesel particulates (n=5) showed a lognormal 
distribution and typically ranged from 20 to 120 nm, with a count median diameter of 
54 nm (geometric standard deviation = 1.7 nm).
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2.3  EXPOSURES TO CONCENTRATED AMBIENT PARTICLES 
 
An important challenge in this field is to establish the relevant physicochemical 
properties of the inhaled particles responsible for observed health effects. A major 
criticism of most mechanistic studies is that the exposure route is artificial and 
therefore not directly comparable to the epidemiological panel studies. In the last few 
years, however, instrumentation has been developed that is designed to deliver a 
continuous flow of air in which the concentration of ambient PM in the sampled air 
stream is increased in real-time by roughly an order of magnitude [Sioutas et al, 
1995; Sioutas et al, 1997]. The advantage of these instruments is that they can 
provide genuine inhalation exposures under controlled conditions. In previous 
studies exposure to fine +ultrafine CAPs has been shown to induce mild pulmonary 
inflammation in healthy adults [Ghio et al, 2000], and to change heart rate variability 
in the elderly [Devlin et al, 2003] and in asthmatic and healthy younger adults [Gong 
et al, 2003].   
 
Our exposures were conducted in collaboration with a group from the Dutch 
National Institute of the Environment (RIVM). The RIVM have developed a Mobile 
Ambient Particle Concentrator Exposure Laboratory (MAPCEL) containing a 
Versatile Aerosol Concentration Enrichment System (VACES) concentrator [Kim et 
al, 2000], with the aim of concentrating fine and ultrafine particles (diameter <2.5 
µm) and delivering them to a human exposure chamber at a flow rate of 50 litre per 
minute. In the first exposure study of its kind, the MAPCEL was transported to 
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Edinburgh to assess the effects of local CAPs on vascular function in patients with 
ischemic heart disease and age-matched healthy controls.  
 
The MAPCEL was situated outside the Royal Infirmary Edinburgh approximately 6 
miles from the city centre (Figure 2.3). A bus route passed adjacent to the MAPCEL 
and an arterial city-route was located a few hundred meters away. The primary 
reason for this choice of location was for safety as this was the first time that an 












Figure 2.3.  Location of the Mobile Ambient Particle Concentrator Exposure 






2.3.1 Enrichment of ambient particulate 
 
A schematic diagram of the MAPCEL and VACES used to deliver CAPs and filtered 
air to human subjects is given in Figure 2.4. Incoming ambient air (500 L/min) is 
saturated with water vapour to increase the size of ultrafine and fine particles 
(PM<2.5 µm) before the air is passed through a series of five virtual impactors. This 
increase in size and therefore mass ensures that particles have sufficient momentum 
to pass through the impactors exiting in the minor flow (5 L/min) in which the 
particle concentration is enriched by a factor of 10-20 fold. Of note particles larger 
than 3 µm are lost by impaction on the walls of the inlet and saturator and do not 
pass through this system. The outward flow from the five impactors (25 L/min) is 
desaturated by silica gel dryers to restore the particles to their original size, and 
diluted with filtered air prior to delivery into the human exposure chamber (50 
L/min) resulting in approximately an 8-fold increase in fine + ultrafine particle 
concentration.  
 
The air in the exposure chamber was continuously monitored for temperature, 
humidity, nitrogen oxides (chemiluminescence NO-NO2-NOx analyser, Thermo 
Environmental Instruments (TEI), USA), CO (gas filter correlation CO analyser, 
TEI, USA), sulphur dioxide (SO2) (pulsed fluorescence SO2 analyser, TEI, USA), 
and ozone (photometric analyser, Measurement Controls Corporation, USA). Particle 
number was determined using a CPC (Model 3022A, Thermo Systems Incorporated, 
USA). Particle mass was continuously monitored using a DataRam nephelometer 
(Measuring Instruments for the Environment Corporation, USA) to standardise diesel 
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exposures, with the precise mass determined by gravimetric filter measurements 
(Teflon 2.0m 4.7mm, PALL Life Sciences, USA). The concentration of CAPs was 
not standardised for all subjects as exposures were dependent on ambient particulate 
levels on the day of the study. We aimed to deliver approximately 200 µg/m3 to 














Figure 2.4. A schematic diagram of the VACES used to deliver concentrated fine 
and ultrafine CAPs and filtered air to human subjects. See text for details. 
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2.3.2  Assessment of particle size and composition 
An Aerosol Time-Of-Flight Mass Spectrometer (ATOFMS) was employed to 
characterise the particulate matter sampled during CAPs exposures. The operation of 
ATOFMS instrument has been described in detail elsewhere and only a brief 
description will be given here [Toner et al, 2006]. After entering into the ATOFMS, 
the particles undergo a jet expansion through a converging nozzle; this results in 
particle velocities ranging from 100 to 400 m/s. The particles then pass through three 
stages of differential pumping and form a particle beam. This narrow beam is 
directed down through the instrument into a light scattering region where the 
aerodynamic diameter of each individual particle is determined. Particles will scatter 
light from two continuous wave 532 nm Nd:YAG lasers positioned orthogonal to 
each other. The signal from the scattered light is sent to a timing circuit that 
calculates the particles velocity and hence the particles diameter as well as 
calculating the arrival time for the particle into the ablation region. When the particle 
arrives in the ablation region, a 266nm Nd:YAG laser is triggered and will ablate the 
particle and ionise the resulting fragments. The positive and negative ions formed 
during the laser desorption-ionisation event will be accelerated down the 
corresponding positive or negative time-of-flight tubes before being recorded by 
micro-channel plate detectors. These signals are then translated into positive and 
negative mass spectra for each individual particle sampled.
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2.4 EXPOSURES TO TECHNETIUM-LABELLED NANOPARTICLES  
 
Radiolabelled carbon nanoparticles have also been delivered to healthy volunteers 
via a system designed for diagnostic radionuclide lung ventilation scanning [Nemmar 
et al, 2002]. Although these particles may differ from those produced by the high 
temperature combustion of fossil fuels, this approach may be a novel way of 
examining the extent to which nanoparticles are capable of translocating from the 
lungs into the systemic circulation.  
 
Technegas was generated using a commercially available generator (Technegas 
generator, Vita Medical Ltd, Sydney) and the manufacturer’s recommended protocol. 
Briefly, 0.14 mL of sodium 99mTc-pertechnetate (Na99mTcO4) solution (2 GBq/mL) 
was added to a graphite crucible. The solution was evaporated to dryness during the 
10-minute simmer phase. The Technegas was then generated during the burn phase 
in which the crucible was resistively heated at 2550oC for 15 seconds in an 
atmosphere of 99.998% argon. A size distribution study of Technegas particles using 
transmission electron microscopy indicated that the majority of particles were 4-20 
nm in diameter 
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2.5 ASSESSMENT OF VASCULAR AND FIBRINOLYTIC FUNCTION 
 
Measuring the response to vasoactive substances released by, or those that interact 
with, the vascular endothelium in the forearm is a useful measure of endothelial 
function. Local intra-arterial drug infusion permits the direct assessment of vascular 
responses without invoking concomitant effects on other organs. In this way the 
vessels are studied in their physiological environment under the influence of 
neuronal, circulating, and local mediators [Benjamin et al, 1995].  Although 
measurement of coronary vascular response is of greatest clinical relevance, invasive 
coronary studies can only really be performed in patients undergoing angiography. 
The close correlation between coronary and peripheral endothelium-dependent 
responses [Anderson et al, 1995] suggests that endothelial dysfunction may be a 
systemic state or that circulating factors have parallel effects in both coronary and 
peripheral arteries [Vita et al, 2004].  
 
2.5.1  Venous occlusion plethysmography 
This method of assessing resistance vessel function in the forearm is based on the 
principle of strain gauge venous impedance plethysmography. This technique 
examines the change in forearm blood flow (FBF) during intra-arterial (brachial 
artery) administration of agonists at locally active doses (Figure 2.5) [Benjamin et al, 

























Figure 2.5 Intra-brachial artery infusions along with venous occlusion (upper 
arm) and supra-systolic pressure (wrist) cuffs in a healthy volunteer. A venous 
cannula for blood sampling is sited in the antecubital vein. 
 54 
The technique of venous occlusion plethysmography relies on intermittently 
preventing venous drainage from the arm using upper arm cuffs inflated to above 
venous pressure whilst arterial inflow is unaltered: blood can enter the forearm but 
cannot escape. This results in a linear increase in forearm volume over time, which is 
proportional to arterial blood inflow (Figure 2.6). Under resting conditions, 
approximately 70% of total forearm blood flow is through skeletal muscle. As the 
hand contains a high proportion of arteriovenous shunts with a different 
pharmacology and physiology it is excluded from the circulation by the application 
of inflation cuffs at supra-systolic pressure during the measurement. The technique 
of bilateral forearm blood flow measurement is highly reproducible within 
individuals [Walker et al, 2001] and is ideally suited to assessment of interventional 
























Figure 2.6  Typical blood flow recording from non-infused and infused arms with 
infusion of intra-brachial bradykinin during venous plethysmography study.
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2.5.2 Brachial Artery Cannulation 
The brachial artery of the non-dominant arm was cannulated with a 27-G steel needle 
(Cooper's Needle Works Ltd, Birmingham, UK) under 1% lidocaine (Xylocaine; 
Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthesia. The cannula was 
attached to a 16-G epidural catheter (Portex Ltd, Hythe, UK) and patency maintained 
by infusion of saline (0.9%: Baxter Healthcare Ltd, Thetford, UK) via an IVAC 
P6000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate of intra-arterial 
infusions was maintained constant throughout all studies at 1 mL/min.  
 
2.5.3 Blood Flow Measurement 
Blood flow was measured in the infused and non-infused forearms by venous 
occlusion plethysmography using mercury-in-silastic strain gauges that were applied 
to the widest part of the forearm [Benjamin et al, 1995]. Both arms were placed 
above the level of the right atrium and upper arm cuffs were inflated intermittently to 
40 mmHg (venous occlusion) pressure for 10 seconds in every 15 seconds to achieve 
venous occlusion and obtain plethysmographic recordings. During measurement 
periods, the hands were excluded from the circulation by rapid inflation of the wrist 
cuffs to a pressure of 220 mmHg (supra-systolic) using E20 Rapid Cuff Inflators 
(D.E. Hokanson Inc., Washington, USA). Analogue voltage output from an EC-4 
strain gauge plethysmograph (D.E. Hokanson Inc.) was processed by a PowerLab® 
analogue-to-digital converter and Chart™ v5.0.1 software (AD Instruments Ltd, 
Oxfordshire, UK) and recorded onto a Dell Latitude® laptop (Dell Computers Ltd, 
UK). Calibration was achieved using the internal standard of the plethysmograph. 
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2.5.4 Plethysmographic Data Analysis 
Plethysmographic data were extracted from the Chart™ data files and forearm blood 
flows were calculated for individual venous occlusion cuff inflations by use of a 
template spreadsheet (Excel 2004; Microsoft Corporation, USA). Recordings from 
the first 60 seconds after wrist cuff inflation were not used because of the variability 
in blood flow that this incurs [Benjamin et al, 1995]. Usually, the last five flow 
recordings in each 3-minute measurement period were calculated and averaged for 
each arm. 
 
2.5.5 Reproducibility of Plethysmographic Data 
A single operator undertook analysis of all data collected during the forearm 
plethysmography studies. The operator was blinded as to whether blood flow data 
was obtained following exposure to filtered air or to particulate air pollution. 
Forearm blood flow responses are reported as absolute blood flow responses 
(mL/100 mL tissue/min) in the infused and non-infused arm. Previous work has 
assessed intra-subject variability and determined the coefficient of variation for 
forearm blood flow across resting conditions and a range of agonists to be between 
24-27% [Walker et al 2001].  
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2.6 VENOUS SAMPLING AND LABORATORY ASSAYS 
 
2.6.1 Forearm Venous Sampling 
Following administration of local anaesthetic, venous cannulae (17-G) were inserted 
into large subcutaneous veins of the antecubital fossa in both arms as described 
previously [Newby et al, 1997]. Blood was withdrawn simultaneously from each arm 
and collected into acidified buffered citrate (Biopool® Stabilyte™, Umeå, Sweden; 
t-PA), trisodium citrate (Monovette®, Sarstedt, Nümbrecht, Germany; PAI-1) 
potassium ethylene diamine tetra-acetic acid (Monovette®, Sarstedt, Nümbrecht, 
Germany; cytokines; full blood count) and serum gel (Monovette®, Sarstedt, 
Nümbrecht, Germany; CRP; clinical chemistry) tubes. 
 
2.6.2 Sample Preparation 
Citrate and acidified buffered citrate samples were centrifuged at 2,000 g for 
30 minutes at 4°C, EDTA samples at 1000g for 10 minutes at 20°C. Serum samples 
were centrifuged at 2,000 g for 20 minutes after being allowed to clot on ice. Platelet 
free plasma or serum was decanted and stored at -80ºC before assay. 
 
2.6.3 Fibrinolytic and Inflammatory Assays 
Plasma PAI-1 and t-PA antigen concentrations were determined by ELISA: TintElize 
(Biopool, Trinity Biotech, Wicklow, Ireland) for t-PA and Coaliza (Chromogenix 
AB, Mölndal, Sweden) for PAI-1. Plasma IL-6, tumor necrosis factor-alpha (TNF-
α), soluble P-selectin, and soluble intracellular adhesion molecule-1 (ICAM-1) were 
measured with commercially available ELISAs (Quantikine, R&D Systems). Intra-
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assay, and inter-assay coefficients of variability were 5.2% and 7.2%, and 4.2% and 
6.4% for plasma TNF-α and IL-6 respectively. Serum CRP concentrations were 
determined using with a validated highly sensitive assay (Department of Clinical 
Biochemistry; Fife NHS Trust, UK) using the method of particle-enhanced 
immunonephelometry (Behring BN II nephelometer, Dade Behring Inc.). Intra-assay 
and inter-assay coefficients of variability for hs-CRP were 3.7% and 4.2% 
respectively. All assays were performed in duplicate and the mean value taken. 
 
Differential white cell count, haematocrit and clinical biochemical assays were 
undertaken on fresh venous samples in Edinburgh (Departments of Haematology and 
Clinical Biochemistry, Lothian NHS University Hospitals Trust, UK) and Umeå 
(Departments of Haematology and Clinical Biochemistry, Umeå Hospital University, 
Sweden).  
 
2.7 DATA ANALYSIS AND STATISTICS 
 
For the forearm studies, estimated net release of t-PA antigen was defined as the 
product of the infused forearm plasma flow (based on the haematocrit, Hct and the 
infused FBF) and the concentration difference between the infused      ([t-PA]Inf) 
and non-infused arms ([t-PA]Non-inf). 
 
Estimated net forearm t-PA release =  FBF x (1-Hct) x ([t-PA]Inf - [t-PA]Non-inf) 
 
Area under the curve (AUC) for the dose-response of t-PA release was calculated. 
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Data were examined, where appropriate, by analysis of variance (ANOVA) with 
repeated measures, two-tailed Student’s t-test and Chi-squared test using GraphPad 
Prism (GraphPad Software, California, USA). Results are expressed as mean and 
standard error of mean (SEM) unless otherwise stated. Statistical significance was 
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Although the mechanisms are unknown, it has been suggested that transient exposure 
to traffic derived air pollution may be a trigger for acute myocardial infarction. The 
study aim was to investigate the effects of diesel exhaust inhalation on vascular and 
endothelial function in man. In a double-blind randomised crossover study, 30 
healthy men were exposed to dilute diesel exhaust (300 µg/m3 particulate 
concentration) or air for one hour during intermittent exercise. Bilateral forearm 
blood flow and inflammatory factors were measured before and during unilateral 
intra-brachial bradykinin (100-1000 pmol/min), acetylcholine (5-20 µg/min), sodium 
nitroprusside (2-8 µg/min) and verapamil (10-100 µg/min) infusions 2 and 6 hours 
following exposure. There were no differences in resting forearm blood flow or 
inflammatory markers following exposure to diesel exhaust or air. Although there 
was a dose dependent increase in blood flow with each vasodilator (P<0.0001 for 
all), this response was attenuated with bradykinin (P<0.05), acetylcholine (P<0.05) 
and sodium nitroprusside (P<0.001) infusions two hours following exposure to diesel 
exhaust and persisted at 6 hours. Bradykinin caused a dose-dependent increase in 
plasma t-PA (P<0.0001) that was suppressed 6 hours following exposure to diesel 
(P<0.001; area under the curve decreased by 34%).  At levels encountered in an 
urban environment, inhalation of dilute diesel exhaust impairs two important and 
complementary aspects of vascular function in man: the regulation of vascular tone 
and endogenous fibrinolysis. These important findings provide a potential 
mechanism that links air pollution to the pathogenesis of atherothrombosis and acute 




Air pollution is a major cause of cardiovascular morbidity and mortality. Short-term 
increases in air pollution exacerbate cardio-respiratory disease leading to 
hospitalisation for conditions including acute myocardial infarction [Peters et al, 
2001a]. Long-term repeated exposure increases the risk of cardiovascular mortality 
with deaths attributable to ischaemic heart disease, arrhythmia, and heart failure 
[Dockery et al, 1993]. These associations are strongest for fine particulate air 
pollutants [Samet et al, 2000], of which the combustion-derived nanoparticulates of 
diesel exhaust are an important component [Laden et al, 2000]. Although significant 
improvements in air quality have occurred over the last 50 years, the association 
between PM2.5 and mortality is evident below current air quality standards [Ware, 
2000].   
 
Despite the strength of the epidemiological evidence and the emergence of promising 
hypotheses [Brook et al, 2004; Pope et al, 2004], the important constituents and 
biological mechanisms responsible for the cardiovascular effects of air pollution are 
largely unknown. It was recently reported that transient exposure to road traffic may 
increase the risk of acute myocardial infarction [Peters et al, 2004]. Long-term 
exposure to traffic in those living within 100 meters of a major road, significantly 
increases cardiopulmonary mortality [Hoek et al, 2002]. These important 
observations suggest that the combustion-derived particulate in PM2.5 may be critical 
in determining the cardiovascular effects of air pollution.   
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Abnormal endothelial function has been widely recognised in patients with 
atherosclerosis and its risk factors [Newby et al, 2001; Newby et al, 1999]. 
Endothelial dysfunction can also predict the likelihood of future cardiovascular 
events and death in patients with coronary artery disease [Heitzer et al, 2001] and in 
at risk individuals with normal coronary arteries [Halcox et al, 2002]. We have 
previously demonstrated endothelial dysfunction in both the peripheral and coronary 
circulation of cigarette smokers [Newby et al, 2001; Newby et al, 1999]. Given the 
potential for common etiological factors contained within air pollution and cigarette 
smoke, we hypothesised that the adverse cardiovascular effects of air pollution are a 
result of combustion derived particulate and are mediated by an impairment of 
normal vascular function. Using a carefully characterised exposure system, the study 
aim was to assess the effect of dilute diesel exhaust inhalation on endothelial 





3.3.1 Subjects  
Thirty healthy male non-smokers between 20 and 38 years old participated in these 
studies which were performed with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki, and the written informed 
consent of all volunteers. Subjects taking regular medication and those with clinical 
evidence of atherosclerotic vascular disease, arrhythmia, diabetes mellitus, 
hypertension, renal or hepatic failure, asthma, significant occupational exposure to 
air pollution, or an inter-current illness likely to be associated with inflammation 
were excluded from the study. Subjects had normal lung function and reported no 
symptoms of respiratory tract infection for at least six weeks prior to or during the 
study. 
 
3.3.2 Study design 
Subjects attended on two occasions two weeks apart and received filtered air or 
diesel exhaust in a randomised double blind crossover design. Each subject was 
exposed for one hour in a specially built diesel exposure chamber according to a 
previously described standard protocol [Rudell et al, 1994]. During each exposure 
they performed moderate exercise (minute ventilation 25 L/min/m2) on a bicycle 
ergometer that was alternated with rest at 15-minute intervals.  
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Based on previous exposure [Salvi et al, 1999] and systemic inflammatory 
[Hingorani et al, 2000] studies, vascular assessments were performed in 15 subjects 
at 6-8 hours following diesel or air exposure. In light of our findings from this 6-8 
hour study, we subsequently determined vascular function in a further 15 subjects at 
an earlier time point of 2-4 hours after exposure to diesel exhaust or air. All subjects 
abstained from alcohol for 24 hours and from food, tobacco and caffeine-containing 
drinks for at least 4 hours before each vascular study. Studies were carried out in a 
quiet, temperature controlled room maintained at 22-24ºC with subjects lying supine. 
All subjects remained indoors between the exposure and vascular assessment to 
minimise additional exposure to particulate air pollution.  
 
3.3.3  Diesel Exposure  
The diesel exhaust was generated from an idling Volvo diesel engine (Volvo TD45, 
4.5 L, 4 cylinders, 680 rpm) as described previously [Salvi et al, 1999]. Over 90% of 
the exhaust was shunted away, and the remaining part diluted with air and fed into 
the exposure chamber at a steady-state concentration. The air in the exposure 
chamber was continuously monitored for NO, NO2, CO, particles (number/cm
3) and 
total hydrocarbons. The exposures were standardised by keeping the particulate 
concentration at 300 µg/m3and were associated with concentrations of NO2 of 1.6 
ppm; NO 4.5 ppm; CO 7.5 ppm; total hydrocarbons 4.3 ppm; formaldehyde 0.26 
µg/m3 and 1.2 x 106 suspended particles/cm3. The temperature and humidity in the 
chamber were controlled at 20ºC and 50% respectively. 
 
3.3.4 Vascular studies 
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All subjects underwent brachial artery cannulation with a 27-standard wire gauge 
steel needle under controlled conditions. Following a 30 min baseline saline infusion, 
acetylcholine at 5, 10 and 20 µg/min (endothelium-dependent vasodilator that does 
not release t-PA; Merck Biosciences, Switzerland), bradykinin at 100, 300 and 1000 
pmol/min (endothelium-dependent vasodilator that releases t-PA ; Merck 
Biosciences, Switzerland) and sodium nitroprusside at 2, 4 and 8 µg/min 
(endothelium-independent vasodilator that does not release t-PA; David Bull 
Laboratories, UK) were infused for 6 min at each dose. The three vasodilators were 
separated by 20 min saline infusions and given in a randomised order. In the second 
cohort with the early (2-4 hour) vascular assessment, verapamil at 10, 30 and 100 
µg/min (endothelium and nitric oxide -independent vasodilator that does not release 
t-PA) was infused at the end of the study protocol [Robinson et al, 2006].  
 
Forearm blood flow was measured in the infused and non-infused arms by venous 
occlusion plethysmography using mercury-in-silastic strain gauges as described 
previously [Newby et al, 1997]. Supine heart rate and blood pressure in the non-
infused arm were monitored at intervals throughout each study using a semi-
automated non-invasive oscillometric sphygmomanometer. 
 
3.3.5 Venous sampling and plasma analysis 
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the ante-
cubital fossae of both arms. Blood (10 mL) was withdrawn simultaneously from each 
arm at baseline and during the infusion of each dose of bradykinin, and collected into 
acidified buffered citrate (Stabilyte tubes, Biopool International) for t-PA assays, and 
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citrate (BD Vacutainer) for PAI-1 assays. Samples were kept on ice before being 
centrifuged at 2000 g for 30 minutes at 4°C. Platelet-free plasma was decanted and 
stored at -80°C before assay. Plasma t-PA and PAI-1 antigen concentrations were 
determined by enzyme linked immunosorbant assays (TintElize t-PA, Biopool EIA; 
Coaliza PAI-1, Chromogenix AB). Haematocrit was determined by capillary tube 
centrifugation at baseline and during infusion of bradykinin 1000 pmol/min.  
 
Blood samples were taken immediately before, 2 and 6 hours after the exposure and 
analysed for total cells, differential count and platelets using an autoanalyzer. Plasma 
IL-6 and TNF- were measured using commercially available enzyme-linked 
immunosorbent assays (Quantikine, R&D Systems, Minneapolis). Plasma 
immunoreactive big endothelin (ET)-1 and ET-1 concentrations were measured 
following an acetic acid extraction technique by use of a modified commercial 
radioimmunoassay with rabbit antihuman big ET-1 or ET-1 (Peninsula Laboratories 
Europe, St Helens, United Kingdom), as described previously [Adam et al, 2001]. 
Serum CRP concentrations were measured using an immunonephelometric assay 
(Behring BN II nephelometer, Marburg, Germany). 
 
3.3.6 Data analysis and statistics 
Plethysmographic data were analysed as described previously [Newby et al, 1999]. 
Estimated net release of t-PA antigen was defined as the product of the infused 
forearm plasma flow (based on the mean haematocrit and the infused forearm blood 
flow) and the concentration difference between the infused and non-infused arms. 
Continuous variables are reported as mean ± SEM. Statistical analyses were 
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performed with GraphPad Prism (Graph Pad Software) using ANOVA with repeated 
measures and two-tailed Student’s t-test where appropriate. The area under the curve 
was calculated for the estimated net release of t-PA during the forearm study period. 





There were no differences in resting heart rate, blood pressure or baseline forearm 
blood flow following exposure to diesel exhaust or air in either cohort (Table 3.1).  
 
Table 3.1 Baseline haemodynamic variables  
   Air   Diesel Significance 
2 hours, n=15    
Heart rate (bpm)   64 ± 3    65 ± 2 P=0.64 
Systolic blood pressure (mmHg) 140 ± 4 148 ± 4 P=0.13 
Diastolic blood pressure (mmHg)   71 ± 3   77 ± 4 P=0.08 
Infused FBF (mL/100 mL tissue/min)     3.3 ± 0.6     3.1 ± 0.4 P=0.45 
Non-infused FBF (mL/100 mL tissue/min)     2.3 ± 0.2     2.6 ± 0.4 P=0.30 
6 hours, n=15    
Heart rate (bpm)   61 ± 2    60 ± 2 P=0.66 
Systolic blood pressure (mmHg) 138 ± 5 138 ± 3 P=0.39 
Diastolic blood pressure (mmHg)   75 ± 2   76 ± 4 P=0.87 
Infused FBF (mL/100 mL tissue/min)     3.1 ± 0.5     2.5 ± 0.2 P=0.25 
Non-infused FBF (mL/100 mL tissue/min)     2.2 ± 0.1     2.4 ± 0.3 P=0.65 
Values are reported as mean ± SEM, two-tailed paired t-test 
 
Leucocyte, neutrophil and platelet count, plasma IL-6, TNF-, Big ET-1 and ET-1, 
and serum CRP concentrations, were not altered by diesel or air exposure (Table 
3.2). 
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Table 3.2 Systemic effects of exposure to diesel exhaust  
 Pre-exposure 2 hours 6 hours 
Air    
Leucocytes (x 109 cells/L) 5.1 ± 0.2 5.6 ± 0.3 5.3 ± 0.3 
Neutrophils (x 109 cells/L) 2.8 ± 0.2 3.3 ± 0.2 3.0 ± 0.2 
Platelets (x 109 cells/L) 217 ± 12 216 ± 9 218 ± 12 
IL-6 (pg/mL) 2.6 ± 1.3 - 3.4 ± 0.8 
TNF- (pg/mL) 16.9 ± 1.1 - 17.8 ± 1.2 
CRP (mg/L) 0.9 ± 0.3 - 0.8 ± 0.2 
PAI-1 antigen (ng/mL) 20.2 ± 3.9 19.2 ± 2.8 18.5 ± 3.7 
t-PA antigen (ng/mL) 6.6 ± 0.6 7.0 ± 0.6 6.0 ± 0.5 
ET-1 (pg/mL) 4.9 ± 0.5 4.9 ± 0.5 4.9 ± 0.4 
Big ET-1 (pg/mL) 28.8 ± 1.5 29.6 ± 2.5 32.2 ± 2.5 
Diesel     
Leucocytes (x 109 cells/L) 5.6 ± 0.3 5.7 ± 0.4 5.1 ± 0.3 
Neutrophils (x 109 cells/L) 2.8 ± 0.2 3.4 ± 0.3 2.9 ± 0.3 
Platelets (x 109 cells/L) 228 ± 14 227 ± 11 221 ± 12 
IL-6 (pg/mL) 2.7 ± 0.7 - 4.3 ± 2.2 
TNF- (pg/mL) 15.3 ± 0.5 - 16.0 ± 0.8 
CRP (mg/L) 1.0 ± 0.4 - 0.7 ± 0.4 
PAI-1 antigen (ng/mL) 16.1 ± 3.0 15.7 ± 3.6 12.8 ± 2.6 
t-PA antigen (ng/mL) 6.0 ± 0.6 5.9 ± 0.6 5.3 ± 0.6 
ET-1 (pg/mL) 4.5 ± 0.4 4.8 ± 0.3 4.8 ± 0.5 
Big ET-1 (pg/mL) 30.2 ± 2.3 31.9 ± 3.7 28.1 ± 2.6 
Values are reported as mean ± SEM 
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Bradykinin, acetylcholine, and sodium nitroprusside caused dose-dependent 
increases in forearm blood flow following both air and diesel exhaust exposure 
(P<0.0001; Figure 3.1). The increase in blood flow was blunted 2 hours following 
exposure to diesel exhaust in response to the infusion of bradykinin (P<0.05), 
acetylcholine (P<0.05) and sodium nitroprusside (P<0.001) and this diminished 
response persisted at 6 hours (Figure 3.2).  In contrast, verapamil induced 






















Figure 3.1  Infused forearm blood flow in subjects 2-4 hours following diesel 
exposure () and air () during intra-brachial infusion of bradykinin, acetylcholine, 
sodium nitroprusside and verapamil: for all dose responses P<0.0001. For diesel 
exposure () versus air (); bradykinin (P<0.05), acetylcholine (P<0.05), sodium 





















Figure 3.2  Infused forearm blood flow in subjects 6-8 hours following diesel 
exposure () and air () during intra-brachial infusion of bradykinin, acetylcholine, 
and sodium nitroprusside: for all dose responses P<0.0001. For diesel exposure () 
versus air (); bradykinin (P<0.05), acetylcholine (P=0.07), sodium nitroprusside 
(P<0.001). 
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Bradykinin caused a dose-dependent increase in plasma t-PA antigen concentrations 
(P<0.0001; Table 3.3) that was reduced 6 hours following diesel exposure (P<0.001). 
The estimated net t-PA antigen release was reduced by 34% 6 hours following 
exposure to diesel (P<0.05; Figure 3.3), but was unaffected at the earlier time point 

















Figure 3.3 Net release of t-PA antigen in subjects 6 hours following diesel exposure 
() and air () during intra-brachial infusion of bradykinin: for both dose responses 



























































































































































































































































































































































































































































































































































































































































































































































































































































This is the first study to demonstrate that inhalation of diesel exhaust, a common 
urban air pollutant, can impair vascular function in man. Using a robust and powerful 
study design, we have assessed two important and complementary aspects of 
vascular function: the regulation of vascular tone and endogenous fibrinolysis. Both 
are impaired and plausibly related to the well-documented cardiovascular effects of 
air pollution. These important findings provide a plausible mechanism that links air 
pollution to the pathogenesis of atherothrombosis and acute myocardial infarction.  
 
3.5.1 Vasomotor function 
Impaired endothelium-dependent and -independent vasomotor function in the 
forearm vascular bed is associated with an increased risk of acute cardiovascular 
events including cardiac death [Heitzer et al, 2001]. We demonstrate that inhalation 
of diesel exhaust impairs vasomotor responses to both endothelium-dependent and -
independent vasodilators at 6 hours. On the basis of this initial study, it is not clear 
whether the impairment is primarily mediated by the vascular endothelium or is a 
result of smooth muscle dysfunction.  However, reduced nitric oxide bioavailability 
in the presence of increased systemic or vascular oxidative stress is an attractive 
hypothesis.  
 
The endothelium is a major target of oxidative stress and this interaction plays an 
important role in the pathophysiology of vascular disease [Lum and Roebuck, 2001]. 
Superoxide radicals produced as a consequence of oxidative stress, combine with 
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nitric oxide to form peroxynitrite, reducing nitric oxide bioavailability in the vessel 
wall and shifting the balance towards vasoconstriction. In vascular smooth muscle 
cells, superoxide inhibits the activity of enzymes, such as soluble guanylyl cyclase 
[Mulsch et al, 1997] and cGMP-dependent protein kinase [Oelze et al, 2000], 
thereby reducing both endothelium-dependent and –independent nitric oxide 
mediated vasodilatation.  
 
We hypothesised that our initial findings were due to the oxidative effects of diesel 
exhaust, and as such, vascular impairment would occur early. In the subsequent 
study, we demonstrate an acute impairment to endothelium-dependent and -
independent vasodilators, but we were also able to show that vasodilation to the 
calcium channel antagonist verapamil was unaffected. This suggests that the 
mechanism of vascular dysfunction involves increased consumption of nitric oxide, 
whether it be endogenously derived from endothelial nitric oxide synthase, or from 
an exogenous source such as sodium nitroprusside. Indeed, in vitro studies provide 
support for this mechanism, with Ikeda et al demonstrating that the incubation of 
aortic ring preparations with diesel exhaust particles results in a dose dependent 
inhibition of acetylcholine-mediated relaxation, an effect abolished by co-incubation 
with superoxide dismutase [Ikeda et al, 1995b]. 
 
Our findings of an acute effect of exposure to air pollution are consistent with recent 
epidemiological studies that report a significant increase in risk of acute myocardial 
infarction as little as two hours after exposure to road traffic [Peters et al, 2004] or an 
increase in PM2.5 [Peters et al, 2001a]. Our studies add to those of Brook et al who 
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demonstrated a reduction in brachial artery diameter immediately after exposure to a 
mixture of concentrate ambient particles and ozone [Brook et al, 2002]. In contrast, 
they did not find an effect on endothelium-dependent or -independent vasodilatation 
using flow mediated and nitro-glycerine induced dilatation. This may reflect 
differences in the potency of the pollution models used or the technique used to 
assess vascular function. Exposures to concentrated ambient particulate are 
inherently variable in magnitude and composition, where as in our study each 
volunteer received a standard exposure to combustion derived particulate of known 
toxicity. Alternatively, it is possible that the vascular effects of particulate matter are 
mediated primarily in the resistance vessels assessed by plethysmography rather than 
in the conduit arteries assessed by ultrasound of the brachial artery. 
 
3.5.2  Fibrinolytic function 
Acute endogenous t-PA release from the endothelium regulates the dissolution of 
intravascular thrombosis and is a critical determinant of cardiovascular outcome. 
This is exemplified by the clinical observation that in approximately 30% of patients 
with acute myocardial infarction, spontaneous reperfusion occurs within 12 hours of 
vessel occlusion. The increased risk of atherothrombosis and myocardial infarction 
in cigarette smokers is at least in part explained by impaired fibrinolytic capacity 
[Newby et al, 2001; Newby et al, 1999].  
 
We have described an impairment in acute endogenous fibrinolytic capacity 
following diesel exhaust inhalation. This abnormality may have prothrombotic 
consequences that could plausibly result in acute cardiovascular events [Peters et al, 
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2004]. Tissue plasminogen activator release was reduced 6 hours following 
exposure, but not at the earlier time point, suggesting that this impairment is 
mediated by an inducible pathway or a change in protein synthesis. Indeed, culture of 
human umbilical vein endothelial cells with particulate matter for 6 hours inhibits 
both the synthesis and release of t-PA in a dose dependent manner [Gilmour et al, 
2005]. Given that cigarette smoking and air pollution share common toxicological 
properties, the present findings are consistent with previous observations in the 
peripheral [Newby et al, 1999] and coronary [Newby et al, 2001] circulations of 
cigarette smokers, and suggest a potential common etiological factor.  
 
3.5.3  Air pollution, oxidative stress and inflammation 
A substantial body of evidence supports a role for oxidative stress in determining the 
toxicity of ambient pollution [Donaldson et al, 2003] and in the pro-inflammatory 
effects of diesel exhaust particles [Baeza-Squiban et al, 1999; Nel et al, 2001]. 
Reactive oxidant species arise not only from the redox potential of the pollutants 
themselves, but also from the activation of alveolar epithelial cells or resident 
macrophage and the recruitment of circulating neutrophils.  
 
The potential for inhaled nanoparticulate air pollution to cause local inflammation is 
not in doubt, and airway neutrophilia has been demonstrated in a healthy volunteer 
study using the same concentration of diesel particulate and exposure system [Salvi 
et al, 1999]. In our study inhaled diesel exhaust was not associated with an increase 
in blood leukocytes, plasma IL-6 and TNF-, or serum CRP concentrations, but this 
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does not rule out the influence of other circulating inflammatory factors, oxidised 
lipids or proteins.  
 
3.5.4  Population risk and exposure 
As an important source of combustion-derived particulate, diesel exhaust is strongly 
implicated in the observed adverse effects of air pollution [Brunekreef and Holgate, 
2002; Laden et al, 2000; Pope et al, 1999]. Particulate matter concentrations can 
regularly reach levels of 300 g/m3 in heavy traffic, occupational settings, and in the 
world’s largest cities [Report, 1994]. Exposure to 300 g/m3 for one hour increases a 
person’s average exposure over a 24 hour period by only 12 g/m3. Changes of this 
magnitude occur on a daily basis in even the least polluted of cities, and are 
associated with increases in cardiorespiratory mortality [Samet et al, 2000]. Our 
model is therefore relevant both in the composition and magnitude of exposure for 
the assessment of short-term health effects in man.  
 
Diesel exhaust is a complex mixture of gases and particles, and from our findings we 
cannot exclude a non-particulate cause of the adverse vascular effects. However, in 
epidemiological studies, particulate matter has been held responsible for the majority 
of the adverse health effects of air pollution [Schwartz, 1994]. Ambient nitrogen 
dioxide can be considered a surrogate for traffic derived pollution [Brunekreef and 
Holgate, 2002], but has little adverse effect in controlled chamber studies even at the 
exposure levels seen here [Ayres, 1998]. There are no reports of the potential adverse 
cardiovascular effects of toxins such as hydrocarbons or formaldehyde. We therefore 
suggest that the vascular effects described above are mediated primarily by diesel 
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exhaust particulate and not its other components, but this needs to be more 
definitively addressed.  
 
3.5.5  Conclusions 
Exposure to increased levels of combustion derived air pollution for as little as one 
hour can impair vasomotor function and endogenous fibrinolysis in man. We provide 
evidence that this may be the result of reduced nitric oxide bioavailability in the 
vasculature, and postulate that this effect is mediated by oxidative stress induced by 
the nanoparticulate fraction of diesel exhaust. These data provide a plausible 
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Exposure to combustion-derived particulate air pollution is associated with an early 
(1-2 hours) and sustained (24 hour) rise in cardiovascular morbidity and mortality. 
We have previously demonstrated that inhalation of diesel exhaust particulate causes 
an immediate (within 2 hours) impairment of vascular and endothelial function in 
man. We investigate the vascular and systemic effects of diesel exhaust 24 hours 
following inhalation in man. Fifteen healthy men were exposed to diesel exhaust 
(particulate concentration, 300 µg/m3) or filtered air for one hour in a double-blind 
randomised crossover study. Twenty-four hours following exposure, bilateral 
forearm blood flow, and inflammatory and fibrinolytic markers were measured 
before and during unilateral intra-brachial bradykinin, acetylcholine, sodium 
nitroprusside and verapamil infusions.  Resting forearm blood flow, blood pressure 
and basal fibrinolytic markers were similar 24 hours following either exposure. 
Diesel exhaust increased plasma cytokine concentrations (tumour necrosis factor-
alpha and interleukin-6; P<0.05 for both) but appeared to reduce acetylcholine 
(P=0.01) and bradykinin (P=0.08) induced forearm vasodilatation. In contrast, there 
were no differences in either endothelium-independent (sodium nitroprusside and 
verapamil) vasodilatation or bradykinin-induced acute plasma t-PA release.  Twenty-
four hours after diesel exposure, there is a selective and persistent impairment of 
endothelium-dependent vasodilatation that occurs in the presence of mild systemic 
inflammation. These findings suggest that combustion-derived particulate air 
pollution may have important systemic and adverse vascular effects for at least 24 




The link between ambient PM air pollution and increased cardio-respiratory 
mortality and morbidity is well established [Brunekreef and Holgate, 2002]. Short-
term exposure to traffic and ambient air pollution is associated with an increased risk 
of early (1-2 h) and delayed (24 h) presentation with acute myocardial infarction, 
[Peters et al, 2001a; Peters et al, 2004] or rehospitalisation for myocardial ischemia 
in patients with prior myocardial infarction [von Klot et al, 2005]. Long-term 
repeated exposure to PM pollution increases the risk of cardiovascular mortality with 
deaths attributable to ischemic heart disease, arrhythmia, heart failure and cardiac 
arrest [Brook et al, 2004; Hoek et al, 2002; Pope et al, 2004] These associations are 
strongest for fine particulate air pollutants (2.5 µm in diameter; PM2.5) [Laden et al, 
2000]. Diesel exhaust emissions are a significant source of PM2.5 in urban 
environments, particularly in Europe where the use of diesel engines in transport has 
increased steadily in recent years [Charron and Harrison, 2005]. As a consequence, 
diesel exhaust exposures have been used as models of PM pollution in experimental 
studies [Rudell et al, 1994; Salvi et al, 1999; Stenfors et al, 2004].  
 
The biological mechanisms underlying the cardiovascular effects of particulate 
matter air pollution are largely unknown, although it has been suggested that 
pulmonary inflammation results in systemic consequences that adversely affect the 
cardiovascular system [Seaton et al, 1995]. In vitro studies, animal models and 
human exposures have clearly established the oxidant and pro-inflammatory nature 
of combustion-derived particulate matter and implied a role for oxidative stress in 
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determining the toxicity of ambient air pollution and the pro-inflammatory effects of 
diesel exhaust particulates [Donaldson et al, 2005a; Donaldson et al, 2005b; Nel et 
al, 2001]. At levels encountered in an urban environment, we have previously 
demonstrated that exposure to diesel exhaust causes a pronounced airways 
inflammation including recruitment of inflammatory cells, the upregulation of 
vascular endothelial adhesion molecules and the enhanced epithelial expression of 
cytokines. These effects are associated with the upregulation of important oxidative 
stress-related transcription factors and MAP kinases in the bronchial epithelium 
[Behndig et al, 2006; Pourazar et al, 2004; Pourazar et al, 2005; Salvi et al, 2000]. 
  
Endothelial dysfunction is widely considered to represent the earliest pathologic 
process in atherosclerosis, [Weissberg, 1999] with established risk factors for 
cardiovascular disease adversely effecting endothelial function [Newby et al, 2001; 
Newby et al, 1999]. In recent studies, we have demonstrated an immediate 
impairment of vascular and endogenous fibrinolytic function in young healthy 
volunteers following exposure to diesel exhaust [Mills et al, 2005]. In the absence of 
systemic inflammation up to six hours after exposure, we suggested that these early 
vascular effects were determined by oxidative stress. The duration of these adverse 
vascular effects are unknown, and the potential for developing later pulmonary and 
systemic inflammatory effects to potentiate vascular dysfunction require further 
investigation. The aim of the present study was to investigate whether there is 
systemic inflammation and sustained vascular dysfunction in healthy volunteers 24 




4.3.1 Subjects  
Fifteen healthy, male non-smokers (mean age 26 years: range 18 to 38) participated 
in the study. Subjects taking regular medication and those with clinical evidence of 
atherosclerotic vascular disease, arrhythmias, diabetes mellitus, hypertension, renal 
or hepatic failure, asthma, significant exposure to occupational air pollution or 
intercurrent illnesses associated with inflammatory diseases were excluded from the 
study. All subjects had normal lung function and reported no symptoms to suggest 
respiratory tract infection for at least six weeks prior to and throughout the duration 
of the study.  
 
4.3.2 Study design 
Subjects were exposed to filtered ambient air and diesel exhaust at a particulate 
matter concentration of 300 µg/m3 for one hour, in a randomised double-blind cross-
over fashion, according to a previously described standard protocol [Rudell et al, 
1994]. The two exposures were performed at least two weeks apart. During each 
exposure, subjects alternated moderate exercise on a bicycle ergometer and rest at 
15-minute intervals. The workload required to generate a ventilation rate of 25 
L/min/m2 body surface was determined for each individual. This ensured that all 
subjects inhaled approximately the same volume of diesel exhaust air pollution and 
that each subject undertook the same amount of physical activity during both filtered 
air and diesel exhaust exposures. Systemic inflammatory markers were collected and 
vascular assessments were performed 24 hours following both exposures. The 
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subjects were asked not to consume alcohol or caffeine containing drinks for 24 
hours and were fasted for at least 4 hours before the vascular assessment. To 
minimize the risk of confounding by exposure to ambient air pollution, the subjects 
remained indoors between the exposure and vascular study.  
 
4.3.3  Diesel Exposure  
The diesel exhaust air pollution was generated from an idling Volvo diesel (Volvo 
TD45, 4.5 L, 4 cylinders, 680 rpm, Volvo, Sweden) engine as previously described 
[Salvi et al, 1999]. To reach a steady state concentration, more than 90 % of the 
diesel exhaust was shunted away and the remaining part diluted with air and fed into 
the exposure chamber. The air in the exposure chamber was continuously monitored 
for the gaseous components NOx, NO, NO2, and total hydrocarbons. Temperature 
and humidity were set at 20°C and 50% respectively. The exposures were 
standardised using continuous monitoring of NOx ensuring a particulate 
concentration of approximately 300 µg/m3. Levels of gaseous pollutants were 
consistent between exposures with a NOx concentration of 4.44±0.02 ppm, NO2 
concentration of 0.82±0.01 ppm, NO of 3.62±0.02 ppm, and total hydrocarbons of 
2.21 ± 0.12 ppm. 
 
4.3.4 Vascular studies 
The vascular studies were carried out in a quiet room with the temperature 
maintained at 22-24°C and with the subject in the supine position. Brachial artery 
cannulation with a 27-standard wire gauge steel needle was performed under 
controlled conditions and followed by a 30-min baseline saline infusion before 
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acetylcholine was infused at 5, 10 and 20 µg/min (endothelium-dependent 
vasodilator that does not release t-PA; Novartis Pharmaceuticals UK Ltd, Frimley 
Surrey, UK), bradykinin at 100, 300 and 1,000 pmol/min (endothelium-dependent 
vasodilator that releases t-PA; Merck-Biosciensies, Läufelfingen, Switzerland) and 
sodium nitroprusside at 2, 4 and 8 µg/min (endothelium-independent vasodilator that 
does not release t-PA; Hospira INC, Lake Forest, Illinois, USA). The three 
vasodilators were infused for 6 min at each dose in a randomised order and separated 
by 20 min saline infusions.  After another 20 min saline infusion, verapamil was 
infused at 10, 30 and 100 µg/min (endothelium- and nitric oxide-independent 
vasodilator that does not release t-PA; Abbott, Solna, Sweden) at the end of the study 
protocol. 
 
Forearm blood flow was measured in both arms by venous occlusion 
plethysmography with a mercury-in-silicone elastomer strain gauges as described 
previously [Newby et al, 1999]. Supine heart rate and blood pressure in the non-
infused arm were monitored at intervals in each study with a semi-automated, non-




Venous cannulae (17-gauge) were inserted into subcutaneous antecubital veins in 
both arms. Ten mL of venous blood was withdrawn simultaneously from each arm at 
baseline and during the infusion of each dose of bradykinin, and collected in 
acidified buffered citrate (Stabilyte tubes, Trinity Biotech Plc, Wicklow, Ireland) for 
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t-PA antigen and into citrate (BD Vacutainer, Plymouth, UK) for PAI-1 antigen 
assays. Plasma samples were kept on ice until centrifuged at 2,000 g for 30 minutes 
at 4°C. Platelet-free plasma was decanted and stored at -80°C before assay. Plasma 
PAI-1 and t-PA antigen concentrations were determined by ELISA: TintElize 
(Biopool, Trinity Biotech, Wicklow, Ireland) for t-PA and Coaliza (Chromogenix 
AB, Mölndal, Sweden) for PAI-1. Haematocrit was determined at baseline and 
during infusion of bradykinin at 1,000 pmol/min.  
 
Blood samples were drawn from the venous cannulae prior to the onset of the 
vascular assessment for preparation of serum and plasma approximately 24-hours 
following each exposure. Plasma IL-6, TNF-α, soluble P-selectin, and soluble 
ICAM-1 were measured with commercially available ELISAs (Quantikine, R&D 
Systems).  
 
Plasma nitrite was measured using high performance liquid chromatography based 
on the methods by Misko TP et al. [Misko et al, 1993]. Total anti-oxidant capacity of 
plasma was measured in Trolox-equivelents as previously described [Miller et al, 
1993]. Serum CRP concentrations were measured with an immunonephelometric 
assay (Behring BN II nephelometer). Whole blood samples were analysed for total 
cells, differential count and platelets by an autoanalyzer according to standard 
clinical methods.  
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4.3.6 Electron paramagnetic resonance (EPR) of diesel particulates 
EPR was used to establish radical generation from diesel particulate. Diesel 
particulate (300µg) was collected on Teflon filters (PTFE Membrane Disc Filter, Pall 
Corporation, Pall Norden AB, Lund, Sweden) during clinical exposures. To remove 
particulate matter, filters were vortexed in 2 mL detergent (0.5% Tween20) and 
particle aggregates broken down by sonication (30 min). 100 µl suspension (particle 
concentration = 150µg/mL) was withdrawn and incubated with the spin-trap, 
Tempone-H (1 mmol/L) immediately before the initial measurement. A blank 
(unexposed) filter was treated in the same way to act as a control. Pyrogallol (100 
µmol/L) was used as positive controls to generate superoxide radicals. In some 
samples superoxide dismutase (SOD; 500 U/mL) was added to scavenge superoxide 
generated in solution. 
 
Samples were kept at 37oC throughout and measurements were taken at t=1, 20, 40 
and 60 min by drawing 50 µl of sample into a capillary tube (Scientific Laboratory 
Ltd, Coatbridge, UK) and sealing with a plug of soft sealant (Cristaseal, VWR 
International, Lutterworth, UK). An X-band EPR machine (Magnettech MS-200, 
Berlin, Germany) was used with the following parameters: microwave frequency, 
9.3-9.55 Hz; microwave power, 20 mW; modulation frequency, 100 kHz; 
modulation amplitude, 1500 mG; center field, 3365 G; sweep width, 50 G; sweep 
time, 30 s; number of passes, 1; receiver gain, 1x101. The intensity scale on all 




All agents were made freshly before experiment and dissolved in Hank’s balanced 
salt solution (Sigma, Poole, UK) except stock solutions of diesel suspension 
(dissolved in 0.5% Tween 20) and Tempone-H (dissolved in 0.01 mol/L EDTA). All 
compounds were purchased from Sigma-Aldrich (Poole, UK) with the exception of 
Tempone-H (Alexis/Axxora, Nottingham, UK). 
 
4.3.7 Data analysis and statistics 
Plethysmographic data were extracted from the Chart data files, and forearm blood 
flows were calculated for individual venous occlusion cuff inflations as described 
previously [Newby et al, 1999]. Recordings from the first 60 seconds after wrist cuff 
inflation were not used because of the reflex vasoconstriction this causes. The last 5 
flow recordings in each 3-minute measurement period were calculated and averaged 
for each arm. Estimated net release of t-PA antigen was defined as the product of the 
infused forearm plasma flow (based on the mean haematocrit and the infused 
forearm blood flow) and the concentration difference between the infused and non-
infused arms.  
 
This study’s population size, on the basis of power calculations derived from 
previous studies, gives 90% power of detecting a 20% difference in t-PA release at a 
significance level of 5%. Continuous variables are reported as mean ± SEM. 
Statistical analyses were performed with GraphPad Prism (Graph Pad Software) 
using ANOVA with repeated measures when comparing dose response to 
vasodilators between exposures, and paired two-tailed Student’s t-test for 
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comparisons between systemic inflammatory and oxidative stress markers. Statistical 






There were no differences in resting heart rate, blood pressure or baseline forearm 
blood flow between or during the two study visits (Table 4.1).  
 
Table 4.1 Haemodynamic variables 24-hours following exposure 
 Air Diesel Significance 
Heart rate (bpm) 62 ± 2 61 ± 2 P=0.73 
Systolic blood pressure (mmHg) 144 ± 3 143 ± 3 P=0.63 
Diastolic blood pressure (mmHg) 71 ± 2 75 ± 2 P=0.16 
Infused FBF (mL/100 mL tissue/min) 3.6 ± 0.5 3.2 ± 0.4 P=0.15 
Non-infused FBF (mL/100 mL tissue/min) 2.5 ± 0.2 2.7 ± 0.2 P=0.48 
Values are reported as mean ± SEM, two-tailed paired t-test 
 
 
4.4.1  Vascular function  
Following both air and diesel exhaust exposures, there were dose-dependent 
increases in the infused forearm blood flow with all vasodilators (P<0.001 for all). 
After exposure to diesel exhaust, endothelium-dependent vasodilatation was reduced 
with acetylcholine (P=0.01) and appeared to be reduced with bradykinin (P=0.08; 
Figure 4.1). In contrast, there were no effects on endothelium-independent 
vasodilatation: peak blood flow responses to sodium nitroprusside (14.2±1.2 vs. 
12.8±0.8 mL/100 mL/min) and verapamil (14.6±0.9 vs. 13.4±0.9 mL/100 mL/min) 
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were similar. Venous plasma concentrations of nitrite were not effected by exposure 
(Table 4.2). 
 
Table 4.2 Systemic effects 24-hrs following exposure to air and diesel exhaust 
 
 Air Diesel Significance 
Leukocytes (x 109 cells/L) 5.2 ± 0.4 5.2 ± 0.3 0.84 
Neutrophils (x 109 cells/L) 2.8 ± 0.2 2.8 ± 0.2 0.57 
IL-6 (pg/mL) 1.5 ± 0.2 2.2 ± 0.2 0.02 
TNF-α (pg/mL) 0.88 ± 0.07 0.99 ± 0.07 0.02 
CRP (mg/mL) 0.75 ± 0.20 0.70 ± 0.19 0.97 
sI-CAM-1 (ng/mL) 171 ± 6 181 ± 8 0.76 
Nitrite (nM) 108.1 ± 6.8 117.7 ± 8.1 0.45 
TEAC (mM) 6.0 ± 0.2 7.1 ± 0.3 0.003 
sP-selectin (ng/mL) 33.7 ± 1.8 36.5 ± 1.4 0.02 
Platelets (x 109 cells/L) 221 ± 12 219 ± 14 0.57 
t-PA antigen (ng/mL) 5.9 ± 0.5 6.2 ± 0.6 0.63 
PAI-1 antigen (ng/mL) 16.8 ± 2.1 19.8 ± 3.5 0.45 
 
Values are reported as mean ± SEM; Student’s t-test (air versus diesel) 



















Figure 4.1  Infused forearm blood flow in subjects following diesel exposure () and 
filtered air () during intra-brachial infusion of bradykinin and acetylcholine. 
P<0.001, for all dose responses in the infused arm. For diesel exposure () versus air 
(); bradykinin (P=0.08) and acetylcholine (P=0.01) 
 
Bradykinin caused a dose-dependent increase in plasma t-PA concentrations 
(P<0.001; Table 4.3) that was unaffected by diesel exhaust exposure. The estimated 





Table 4.3  Forearm blood flow and plasma t-PA antigen concentrations 
 Air 
Bradykinin, pmol/min 0 100 300 1000 
FBF, mL/100 mL/min  
   Non-infused arm 2.2 ± 0.2 2.3 ± 0.2 2.2 ± 0.1 2.6 ± 0.3 
   Infused arm 4.8 ± 1.0 12.3 ± 1.4 14.8 ± 1.5 20.2 ± 2.0* 
t-PA antigen, ng/mL  
   Non-infused arm 6.2 ± 0.5 6.0 ± 0.5 6.0 ± 0.6 7.8 ± 0.6 
   Infused arm 6.0 ± 0.5 7.9 ± 0.7 10.1 ± 0.8 14.0 ± 0.9* 
 Diesel 
Bradykinin, pmol/min 0 100 300 1000 
FBF, mL/100 mL/min  
   Non-infused arm 2.6 ± 0.3 2.6 ± 0.2 2.5 ± 0.2 2.5 ± 0.3 
   Infused arm 4.1 ± 0.7 10.7 ± 1.0 13.8 ± 1.1 18.8 ± 1.2* 
t-PA antigen, ng/mL  
   Non-infused arm 6.0 ± 0.6 6.4 ± 0.5 6.7 ± 0.6 8.4 ± 0.6 
   Infused arm 6.2 ± 0.6 7.8 ± 0.7 10.6 ± 1.0 14.7 ± 1.3* 
Values are reported as mean ± SEM 





4.4.2 Systemic inflammation and oxidative stress 
Twenty-four hours following the exposures, there were no differences in leukocyte, 
and neutrophil counts, or plasma soluble ICAM-1, t-PA and PAI-1 antigen 
concentrations (Table 4.2). Exposure to dilute diesel exhaust increased plasma IL-6 
(2.2±0.2 versus 1.5±0.2 pg/mL, P=0.02) and TNF-α (0.99±0.07 versus 0.88±0.07 
pg/mL, P=0.02) concentrations compared with air.  Total platelet numbers were not 
affected by exposure, but concentrations of soluble P-selectin were increased 24-
hours after exposure to diesel exhaust (36.5±1.4 versus 33.7±1.8 ng/mL, P=0.02).  
Leucocyte, neutrophil and platelet count, plasma IL-6, TNF-, Big ET-1 and ET-1, 
and serum CRP concentrations, were not altered by diesel or air exposure. 
 
Total anti-oxidant capacity of plasma was greater 24 hours following exposure to 
diesel exhaust compared to filtered air (Table 4.2). Suspensions of diesel exhaust 
particles showed a time-dependent increase in the characteristic 3-peak EPR 
spectrum for a spin-adduct with the unpaired electron in the vicinity of a nitrogen 
atom, ie. 4-oxo-tempo, the oxidised form of Tempone-H (Figure 4.3a). The signal 
increased at a constant rate over the 60 min period. EPR measurements were 
approximately 5-fold higher in suspensions that contained diesel filters (blank, 1144 
units; diesel, 5864 units; t=60 min; Figure 4.3b). SOD inhibited the EPR signal from 
diesel, causing a 30.2% reduction in signal. This concentration of SOD had a similar 
magnitude of effect on the diesel signal as it did to that of the superoxide generator, 
pyrogallol (34.7% reduction; Figure 4.3b).  
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Figure 4.3 (a) Sample EPR spectra generated from suspensions of blank and diesel 
particulate-coated filters, as well as the superoxide generator pyrogallol. EPR spectra 
were generated in the presence (grey lines) and absence (black lines) of SOD. (b) 
Amplitude of EPR spectra (in arbitrary units) over 60 minute incubation period in the 
presence (open symbols) and absence (closed symbols) of SOD. Diesel particulate 
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(square symbols) caused a large increase in EPR intensity in comparison to 
suspension from the blank filter (circles). SOD caused an approximate 30% 
reduction in the EPR signal from diesel particulate and a similar reduction in signal 




Twenty-four hours after a transient one-hour exposure to diesel exhaust, there is a 
selective and persistent impairment of endothelium-dependent vasodilatation that 
occurs in the presence of mild systemic inflammation following a period of potential 
oxidative stress. These findings suggest that combustion-derived particulate air 
pollution may have important adverse systemic and vascular effects for at least 24 
hours following exposure. This may account for the epidemiologic observations of a 
delayed peak in adverse cardiovascular outcomes following exposure to air pollution. 
 
Exposure to air pollution causes airways inflammation and has an important negative 
effect on respiratory health. Diesel exhaust causes neutrophilic airway inflammation 
6 to 24 hours following exposure, [Nordenhall, 2000; Salvi et al, 1999; Stenfors et 
al, 2004] increases airways anti-oxidant defences, and activates redox-sensitive 
transcription factors in vivo, consistent with oxidative stress-induced and cytokine-
mediated inflammation [Mudway et al, 2004]. It is increasingly recognised that these 
effects may induce important systemic effects [Nemery and Abraham, 2005]  
including vascular inflammation [Sun et al, 2005a].  
 
We hypothesised that our initial observations of an immediate (within 2 hours) 
impairment of vascular function were due to the oxidative effects of diesel exhaust 
[Mills et al, 2005]. Following exposure to diesel exhaust, endothelium-dependent 
and -independent nitric oxide donors caused reduced vasodilatation, whilst the 
endothelium- and nitric oxide-independent vasodilator, verapamil, caused normal 
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vasodilatation. This pattern of vascular dysfunction suggested increased consumption 
of nitric oxide, whether it be endogenously derived from endothelial nitric oxide 
synthase or from an exogenous source such as sodium nitroprusside.  
 
In the current study, we demonstrate a persistent endothelium-dependent vascular 
dysfunction 24 hours following an hour-long exposure to diesel exhaust. Whilst 
vasodilatation to both endothelium dependent agonists appeared to be impaired, this 
only reached statistical significance for acetylcholine. Bradykinin causes 
vasodilatation through the release of various endothelium-derived factors including 
nitric oxide, although it is thought that hyperpolarising factor is the primary mediator 
of this response in man [Honing et al, 2000]. It is possible that differences in 
acetylcholine mediated and bradykinin-mediated vasodilatation may be explained by 
variation in the relative contribution of nitric oxide to the vasomotor response of 
these agonists. The mechanism of this selective impairment of endothelium-
dependent vasodilatation has not been determined but we suggest that this may be 
due to modification of endothelial homeostatic pathways following an initial 
oxidative burst.  
 
The role of vascular oxidative stress in mediating endothelial dysfunction in this 
clinical model requires confirmation. However, the mechanism is supported by in 
vitro studies, [Ikeda et al, 1995a; Ikeda et al, 1998; Sun et al, 2005b] as well as 
human exposure studies by our own group [Mills et al, 2005] and others [Brook et 
al, 2002]. The endothelium is a major target of oxidative stress and this interaction 
plays an important role in the pathophysiology of vascular disease [Lum and 
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Roebuck, 2001]. Incubation of aortic ring preparations with diesel exhaust particles 
inhibits acetylcholine-mediated relaxation, an effect that can be reversed by co-
incubation with the free radical scavenger superoxide dismutase [Ikeda et al, 1995b]. 
Furthermore, diesel exhaust particles can induce oxidative modification of low-
density lipoprotein (LDL), the major determinant of atheromatous vascular disease 
[Ikeda et al, 1995a].  
 
Diesel exhaust is a complex mixture of gases and particles, and from our findings we 
cannot exclude a role for non-particulate or soluble components. Whether diesel 
particulates or soluble components of the exposure, including organic hydrocarbons 
and transition metals, can directly affect the systemic vascular endothelium 
following inhalation also requires clarification. Although evidence that inhaled 
nanoparticles can translocate into the circulation in man remains controversial, [Mills 
et al, 2006; Nemmar et al, 2002] it is not in doubt that diesel exhaust particulates are 
capable of inducing oxidative stress in vitro, with reactive oxidant species arising 
from the redox potential of the particles themselves and from the activation of 
inflammatory cells. Using electro-paramagnetic resonance we demonstrate that 
diesel exhaust particulate is capable of generating oxidative free radicals without 
prior interaction with pulmonary or vascular tissue. Furthermore, co-incubation of 
diesel particles with SOD partially prevented this response indicating a contribution 
of superoxide to this oxidative signal. However, measuring systemic oxidative stress 
in vivo is difficult, as the oxidative state is modulated by a range of anti-oxidant 
defences [Behndig et al, 2006]. Interestingly we demonstrate an increase in the anti-
oxidant capacity of plasma 24-hours following exposure to diesel exhaust, perhaps 
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suggesting upregulation of anti-oxidant defence mechanisms following earlier 
systemic oxidative stress. 
 
In contrast to our previous study, stimulated release of endothelial t-PA from the 
forearm circulation was not impaired at 24 hours [Mills et al, 2005]. In health, the 
vascular endothelium delicately balances regulatory pathways controlling 
coagulation, fibrinolysis and inflammation, as well as regulating vascular tone. It is 
perhaps not surprising that these complex dynamic functions are altered by exposure 
to diesel exhaust at different time points. Endogenous fibrinolytic function was 
impaired at 6-8 hours in our previous studies, but has normalised at 24 hours, 
suggesting that this aspect of endothelial homeostasis recovers earlier than 
vasomotor function following exposure to air pollution.  
 
We did not find evidence of a systemic cellular inflammatory response, but did 
identify changes in pro-inflammatory cytokines IL-6 and TNF-alpha raising the 
possibility that ongoing airways inflammation is contributing to the state of vascular 
dysfunction. Observational studies have strongly implicated systemic inflammation 
as a key pathological mechanism in the health effects of particulate matter [Brook et 
al, 2004]. In panel and population studies, increased PM exposure is associated with 
an acute phase response with raised serum CRP concentrations, [Peters et al, 2001b] 
increased plasma viscosity [Peters et al, 1997] as well as altered haematological 
indices [Seaton et al, 1999] and plasma fibrinogen [Ghio et al, 2000; Pekkanen et al, 
2000]. It is possible that in a susceptible population, in which inflammatory 
pathways may be upregulated and anti-oxidant defences may be depleted, an hour 
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long exposure to diesel exhaust would be sufficient to cause a greater systemic 
inflammatory response. Likewise, repeated exposure over a number of days or weeks 
may result in inflammation, with prolonged vascular dysfunction contributing to the 
pathogenesis of atherosclerosis. Indeed, in an ApoE–/– mouse model, long-term 
exposure to low concentration of PM2.5 altered vasomotor tone,
 induced vascular 
inflammation and potentiated atherosclerosis [Sun et al, 2005a]. 
  
Endothelial dysfunction characterised as an impaired vasodilatation to acetylcholine 
predicts the likelihood of future cardiovascular events and death in patients with 
coronary artery disease [Heitzer et al, 2001] and in at risk individuals with normal 
coronary arteries [Halcox et al, 2002]. Whilst the mechanism of this association has 
not been precisely identified, this vascular dysfunction clearly has important clinical 
implications. Our findings of endothelial dysfunction 24 hours following diesel 
exhaust inhalation suggests that the adverse cardiovascular effects of combustion-
derived air pollution are mediated through persistent detrimental vascular effects. 
 
Conclusions 
In healthy volunteers, inhalation of dilute diesel exhaust for one hour, at particle 
concentrations encountered in an urban setting, causes mild systemic inflammation 
and an impairment of vascular endothelial function that persisted for up to 24 hours 
after the exposure. This occurred in the absence of alterations in endogenous 
fibrinolytic capacity. These findings provide a plausible explanation for the observed 
increase in acute cardiovascular events 24 hours following a peak in traffic-related 
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Increased exposure to particulate air pollution is a risk factor for death and 
hospitalisation with cardiovascular disease. It has been suggested that the 
nanoparticulate component of PM10 is capable of translocation into the circulation 
with the potential for direct effects on the vasculature. The study aim was to 
determine the extent to which inhaled Technetium-99m (99mTc) labelled carbon 
nanoparticles (Technegas), were able to access the systemic circulation. Ten healthy 
volunteers inhaled Technegas and blood samples were taken sequentially over the 
following 6 hours. Technegas particles were 4-20 nm in diameter and aggregated to a 
median particle diameter of approximately 100 nm. Radioactivity was immediately 
detected in blood, with levels increasing over 60 minutes. Thin layer chromatography 
of whole blood identified a species that moved with the solvent front, corresponding 
to unbound 99mTc-pertechnetate, which was excreted in urine. There was no evidence 
of particle-bound 99mTc at the origin. Gamma camera images demonstrated high 
levels of Technegas retention (95.6±1.7% at 6 hours) in the lungs, with no 
accumulation of radioactivity detected over the liver or spleen. The majority of 
99mTc-labelled carbon nanoparticles remain within the lung up to six hours after 
inhalation. In contrast to previous published studies, thin layer chromatography did 
not support the hypothesis that inhaled Technegas carbon nanoparticles pass directly 




Epidemiological studies have demonstrated that exposure to air pollution is an 
important risk factor in the development of cardiovascular disease [Dockery et al, 
1993; Pope et al, 2004; Samet et al, 2000]. The WHO identifies particulate matter 
with an aerodynamic diameter of less than 10 µm (PM10) as the most hazardous 
component of air pollution. However, only fine particles with a diameter less than 
2.5 µm (PM2.5) are able to penetrate to the terminal bronchioles and proximal alveoli 
to any great extent. Nanoparticles have a diameter of less than 0.1 µm, and whilst 
constituting a small fraction of the total mass of ambient particulate matter, they 
represent a substantial proportion in terms of particle number. Toxicologists suggest 
that the nanoparticulate component of ambient particulate matter is the most potent 
and likely to be responsible for adverse cardiovascular health effects [Donaldson et 
al, 2001].   
 
The precise mechanism by which air pollution influences cardiovascular risk has not 
been determined. However, a number of interesting hypotheses have been proposed 
to explain how inhaled particles could interact with the cardiovascular system [Brook 
et al, 2004]. The traditional view is that inhaled particles provoke an inflammatory 
response in the lungs, with consequent release of prothrombotic and inflammatory 
cytokines into the circulation [Seaton et al, 1995]. However, a recent publication by 
Nemmar et al suggests that inhaled insoluble nanoparticles may be capable of rapid 
translocation into the circulation [Nemmar et al, 2002], with the potential for direct 
effects on haemostasis or cardiovascular integrity. They used an aerosol of 
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Technetium-99m (99mTc) labelled carbon nanoparticles, ‘Technegas’, which is used 
routinely in clinical practice for radionuclide lung ventilation imaging. Primary 
Technegas particles are 7-23 nm in diameter and aggregate to a mean particle 
diameter of approximately 100 nm [Lemb et al, 1993]. Thin layer chromatography of 
whole blood identified the presence of 99mTc-labelled carbon nanoparticles in the 
bloodstream as early as 1 minute after Technegas inhalation.  
 
Whilst a number of relevant studies have been conducted in animals [Nemmar et al, 
2001; Oberdorster et al, 2002], the work by Nemmar and colleagues is the only study 
to date that suggests translocation of insoluble inhaled nanoparticulate to the 
circulation in man. Alternative explanations for Nemmar’s findings have been 
proposed, which focus on the method of Technegas generation (Brown et al, 2002; 
Burch, 2002). In particular, the rapid clearance of 99mTc from the lungs in this study 
suggests the presence of large quantities of soluble unbound 99mTc in both the aerosol 
and bloodstream. The original study did not report the proportion of 99mTc remaining 
in the lung, preventing comment on the importance of this clearance mechanism. As 
part of a study into the vascular effects of combustion-derived nanoparticulate, we 




5.3.1 Subjects  
Ten healthy non-smoking volunteers (5 male, 5 female; aged 21 to 24 years) 
participated in the study, which was undertaken with the approval of the local 
research ethics committee, in accordance with the Declaration of Helsinki, and the 
written informed consent of each subject. Volunteers were life-long non-smokers 
with normal lung function and no regular exposure to dust or passive smoke in the 
workplace. None of the volunteers had infective illnesses or received medication 
other than oral contraception in the week before the study.  
 
5.3.2 Study design 
Immediately after aerosol generation, subjects inhaled approximately 100 MBq of 
Technegas in 3 breaths via a mouthpiece according to standard clinical procedure 
[Cook and Clarke, 1992]. Subjects rinsed their mouth with water following 
inhalation to minimize delivery to the gastrointestinal tract. Blood samples for thin-
layer chromatography and measurement of activity in the bloodstream and were 
collected via a 17 gauge intra-venous cannula into 2.9 mL citrated blood tubes 
(Sarstedt-Monovette) at 1, 10, 30, 60 and 360 minutes after Technegas inhalation. A 
urine sample was collected 60 minutes after inhalation. The activity of each sample 
was measured with a gamma counter (Cobra II Auto-Gamma, Packard Bioscience 
Company), decay corrected to the time of Technegas inhalation, and expressed as 
counts per minute per gram of whole blood or urine. 
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5.3.3 Technegas generation  
Technegas was generated using a commercially available generator (Technegas 
generator, Vita Medical Ltd, Sydney) and the manufacturer’s recommended protocol. 
Briefly, 0.14 mL of sodium 99mTc-pertechnetate (Na99mTcO4) solution (2 GBq/mL) 
was added to a graphite crucible. The solution was evaporated to dryness during the 
10 minute simmer phase. The Technegas was then generated during the burn phase 
in which the crucible was resistively heated at 2550oC for 15 seconds in an 
atmosphere of 99.998% argon. 
 
To obtain samples for in vitro studies, Technegas was drawn through 10 mL of liquid 
in a conical flask; distilled water for electron microscopy and 0.9% sodium chloride 
in water for thin-layer chromatography. 
  
5.3.4 Particle sizing 
Samples for particle sizing by transmission electron microscopy were prepared by 
placing one drop of the Technegas suspension on a copper grid coated with a carbon 
film. The grid was left to dry in air at room temperature. Particles were sized using a 
transmission electron microscope (JEM-1200EX, JEOL, USA) working at 80 kV. 
Particle size distribution was evaluated using an automatic image analyser and 
Origin software (Microcal, Northampton, USA).  The size distribution of aggregates 
in the aerosol was measured at the outlet of the Technegas generator by a Scanning 
Mobility Particle Sizer (SMPS, TSI Inc, USA) that consists of a Condensation 
Particle Counter (CPC) and a Differential Mobility Analyzer (DMA), and can detect 
aerosol particles in the size range from 7 to 487 nm. 
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5.3.5 Thin layer chromatography 
Thin layer chromatography (TLC) was performed on 20 x 2.5 cm silica gel 
impregnated glass fibre plates (ITLC-SG, Pall Corporation, USA) with a mobile 
phase of 0.9% sodium chloride in water. A 50 µL blood sample was applied 2.5 cm 
from the bottom of the plate. The plate was placed immediately in the mobile phase 
and the solvent front was allowed to rise 12 cm. The plate was cut into 1 cm high 
transverse strips starting 0.5 cm below the origin. This resulted in 13 strips. These 
were placed into tubes in pairs with only a single strip in the final tube. The count-
rate from each tube was measured using an automatic gamma counter (Cobra TM II 
Auto-Gamma, Packard Bioscience Company). Each strip was counted for 10 
minutes. The chromatogram was constructed by expressing the count-rate from each 
tube as a percentage of the total of the count-rates from all seven tubes. A blood 
sample from one subject was analysed in triplicate to assess repeatability of the thin-
layer chromatographic technique. 
 
Control samples consisting of Technegas in 0.9% sodium chloride solution, sodium 
99mTc-pertechnetate solution, whole blood + Technegas solution and whole blood + 
sodium 99mTc-pertechnetate solution were prepared and analysed by thin-layer 
chromatography. The potential for dissociation of the particle-bound 99mTc in 
Technegas to unbound 99mTc-pertechnetate in vitro was assessed by thin-layer 
chromatography of the Technegas sample in 0.9% sodium chloride solution at 1, 60 
and 360 minutes after aerosol generation.  
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5.3.6 Radionuclide imaging 
Between 0 and 5 minutes after inhalation of the Technegas, a static image of the 
thorax was acquired with a GE Millennium gamma camera (GE Millennium gamma 
camera, GE USA). This was followed by the acquisition of 10 dynamic abdominal 
images between 5 and 55 minutes. Further 5-minute static thoracic and abdominal 
images were acquired at 60 and 360 minutes to assess pulmonary retention of 99mTc. 
 
5.3.7 Data analysis 
All results include a correction for background radioactivity and the decay of 99mTc 
(half-life = 6.02 hours), with values presented as mean ± SEM. The total amount of 
radioactivity in the lung was recorded as total counts from each 5 minute static image 
taken at 0, 60 and 360 minutes. The bladder, left and right upper quadrants of the 
abdomen were selected as regions of interest on the dynamic scans. Radioactivity 
within each region of interest was recorded as counts per pixel from each 5-minute 





5.4.1 Particle size 
A size distribution study of Technegas particles (n=1,500) using transmission 
electron microscopy indicated that the majority of particles were 4-20 nm in diameter 
(Figure 5.1). There appeared to be a bimodal distribution, where more than two 
thirds of all particles were less than 10 nm in diameter with a mode of 4 nm, one 
third were larger with a mode of 15 nm, and rare aggregates were seen of up to 200 
nm. Inhaled particles also had a bimodal distribution with the first peak, due to 
primary particles, increasing exponentially to the lower detection limit of the SMPS 
at 7 nm. The size of aggregated particles showed a lognormal distribution and 
typically ranged from 50 to 150 nm, with a count median diameter of 108 nm 









Figure 5.1  (a) Transmission electron micrograph of Technegas particles and (b) a 
size distribution study of 1,500 Technegas particles. 
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Figure 5.2  Radioactivity measured as counts per minute (CPM) per gram of whole 
blood at intervals after inhalation of Technegas. Values are mean ± SEM.  
 
Radioactivity was detected in whole blood within the first minute, reaching a 
maximum at 60 minutes, and declining thereafter (Figure 5.2). In the chromatograms 
obtained from blood samples taken at 1, 10, 30, and 60 minutes after Technegas 
inhalation there is little evidence of 99mTc at the origin, but a consistent peak trailing 
the solvent front is seen at all time points (Figure 5.3). The large error bar at the 
origin, seen at 1 minute, was due to a single outlier. A small peak was present at the 




Chromatography of sodium 99mTc-pertechnetate solution results in a single peak at 
the solvent front (Figure 5.4A). Chromatography of Technegas aerosol solution 
(Figure 5.4B) results in two peaks, one at the origin and one at the solvent front. This 
is consistent with the presence of both particle-bound 99mTc and unbound 99mTc-
pertechnetate. The ratio of particle-bound 99mTc to unbound 99mTc-pertechnetate did 
not change over 360 minutes, suggesting that the Technegas aerosol contained both 
particle bound and unbound 99mTc at the onset, and that dissociation of 99mTc from 
the particles does not occur in vitro. A single peak is seen at the solvent front in urine 
sampled 60 minutes after Technegas inhalation (Figure 5.4C), suggesting that 
unbound 99mTc-pertechnetate or a similar species is excreted in the urine.  
 
Peaks are identified at the origin and trailing the solvent front when Technegas 
aerosol solution was added to whole blood (Figure 5.4D). The addition of sodium 
99mTc-pertechnetate solution to whole blood produces a single peak trailing the 
solvent front, with no peak at the origin or front (Figure 5.4E). It is probable that this 
peak is due to 99mTc-pertechnetate held up by an interaction with one of more 
components in blood. Replication of chromatography on a single blood sample 














Figure 5.3 Thin-layer chromatograms from whole blood samples taken 1, 10, 30, 60 

















Figure 5.4 Thin-layer chromatography controls: (A) Sodium 99mTc-pertechnetate, 
showing a single peak at the solvent front; (B) Technegas aerosol showing two 
peaks, one at the origin and the other at the solvent front, immediately (•), 60 (*) and 
360 () minutes after aerosol collection; (C) Urine sample 60 minutes after 
inhalation showing a single peak at the solvent front; (D) Technegas aerosol added to 
whole blood showing peaks at the origin and trailing the solvent front; (E) Sodium 
99mTc-pertechnetate, added to whole blood showing a single peak trailing the solvent 
front; (F) Replication of chromatography on a single blood sample. Values are mean 
± SEM. 
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Figure 5.5.  (A) Typical antero-posterior lung images at 1, 60 and 360 minutes after 
inhalation of Technegas. Values of retention are mean ± SEM. (B) Typical antero-
posterior and postero-anterior abdominal images recorded at 360 minutes post 
inhalation of Technegas. 
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The average decrease in lung radioactivity was 3.2±0.7% over the first hour, and 
1.2±1.7% over the subsequent 5 hours (Figure 5.5A).  Radioactivity was present 
within the gastrointestinal tract and bladder, but no obvious uptake of 99mTc by the 
liver or spleen was detected (Figure 5.5B). The level of radioactivity over the bladder 













Figure 5.6. Time-activity curve over bladder, right and left upper quadrants 





Air pollution has been consistently linked to adverse cardiovascular events [Dockery 
et al, 1993; Pope et al, 2004; Samet et al, 2000], however the mechanism responsible 
for this association is not well understood. Rapid translocation of inhaled 
nanoparticles into the systemic circulation with direct effects on the vasculature 
could potentially explain this association with cardiovascular risk. However, using 
99mTc-radiolabelled carbon nanoparticles, we found no evidence to support this 
hypothesis. 
 
Following inhalation of Technegas, 99mTc was immediately detected in blood, with 
levels increasing steadily over the first 60 minutes. Thin layer chromatography of 
whole blood identified a species that moved with the solvent, corresponding to 
unbound 99mTc-pertechnetate, but no evidence of significant particle-bound 99mTc at 
the origin. Gamma camera images demonstrated high levels of 99mTc retention 
(96.8±0.7% at 1 hour) in the lungs. Losses were explained by the accumulation of 
99mTc in the bladder (3.4±1.0%), which was confirmed as 99mTc-pertechnetate by 
chromatography of urine.  
 
Nemmar et al also detected 99mTc in the bloodstream immediately following 
inhalation of Technegas. In contrast, the majority of 99mTc remained at the origin of 
the chromatogram, suggesting the presence of circulating particle-bound 99mTc. In 
addition, substantial quantities of radioactivity were measured over the liver and 
other extra-thoracic organs. The authors concluded that inhaled particle-bound 99mTc 
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rapidly translocates into the circulation with particulate accumulating in the 
endoreticular system. Differences in aerosol composition, radionuclide imaging and 
chromatography between our study and that of Nemmar et al merit further 
discussion.  
 
In the presence of even minute quantities of oxygen, the Technegas generator 
produces a mixed aerosol of 99mTc labelled particles and soluble oxides of 99mTc-
pertechnetate (Pertechnegas). Therefore the presence of 99mTc activity in the 
bloodstream or over extra-thoracic organs does not in itself provide evidence of 
particle translocation. Pertechnegas is cleared from the lungs with a half-life of 
approximately 10 minutes [Mackey et al, 1997], and has been used clinically to 
assess lung epithelial permeability [Monaghan et al, 1991]. Pertechnegas and the free 
radiolabel 99mTc-pertechnetate behave similarly on chromatography [Tominaga et al, 
1995], have identical clearance kinetics following inhalation [Isawa et al, 1995], and 
identical distributions following intravenous infusion [Tominaga et al, 1995]. The six 
hour retention of approximately 95% of inhaled 99mTc in our study is consistent with 
rates quoted by the manufacturer [Burch, 2002] and previous independent studies 
[Brown et al, 2002]. The loss of 5% of 99mTc over and above decay occurred within 
the first hour, with little further loss over the remaining five hours. The time course 
of this clearance pattern is highly suggestive of the diffusion of small quantities of 
Pertechnegas into the bloodstream.  
 
Abdominal images demonstrate a clear increase in radioactivity in the bladder, which 
accounted for the loss of lung radioactivity after 60 minutes. Chromatography 
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confirmed that the activity in the bladder was due to 99mTc-pertechnetate in the urine. 
The presence of soluble 99mTc in the Technegas aerosol, the blood stream and in 
urine, strongly suggest that a small amount of 99mTc in the aerosol produced by our 
generator was in the form of 99mTc-pertechnetate or Pertechnegas, which diffused 
rapidly into the circulation and was eliminated via the renal tract.  
  
In the study by Nemmar et al, radioactivity over the bladder was present early and 
increased steadily with as much as 25% of total initial lung radioactivity present in 
the bladder at 45 minutes; chromatography confirmed that this activity was due to 
99mTc-pertechnetate in urine. In addition, 10% of the initial lung radioactivity was 
present in the liver after 5 minutes and there were large quantities of radioactivity 
visible and unaccounted for in the thyroid, salivary glands and stomach. From their 
data, we can infer that pulmonary retention of 99mTc after 45 minutes would be no 
more than 65% although this value was not formally reported. This is in stark 
contrast to previous studies and the present study, and led to the highly plausible 
suggestion from one correspondent that large quantities of soluble 99mTc had been 
produced by a generator contaminated with oxygen [Burch, 2002].  
 
Given the very low pulmonary retention rates and the rapid accumulation of 99mTc-
pertechnetate in urine, it is surprising that chromatography of the aerosol in 
Nemmar’s study suggests it consisted only of 99mTc-labelled particles with no 99mTc-
pertechnetate or Pertechnegas. Despite using the same generator and purity of argon, 
this was not the case in our study or in a previous study [Scalzetti and Gagne, 1995]. 
Scalzetti and Gagne used thin layer chromatography to investigate the effect of 
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increasing the ratio of oxygen: argon in the generator on the transition of Technegas 
to Pertechnegas. When using the recommended highly purified argon (99.998% 
purity) as in our study, they still found approximately 20% of the 99mTc migrated 
with the solvent front. In oxygen concentrations of 0.1% or more an abrupt transition 
from Technegas to Pertechnegas occurred with more than 50% of the 99mTc moving 
with the solvent front [Scalzetti and Gagne, 1995].  
 
Approximately 5% of inhaled 99mTc in our study was in the form of unbound 99mTc-
pertechnetate and diffused rapidly into the circulation before elimination via the 
renal tract. Thin-layer chromatography identified this small quantity of 99mTc-
pertechentate in the blood stream as a consistent and reproducible peak trailing the 
solvent front. In the study by Nemmar et al, 25% of 99mTc was filtered by the 
kidneys within the first 45 minutes, yet chromatography did not reliably identify 
unbound 99mTc-pertechnetate in the blood stream; the largest peak occurred at the 
origin and was ascribed to particle bound 99mTc. To explain the lack of consistency 
between chromatograms of the aerosol, blood and urine, Nemmar et al suggest that 
soluble oxides of 99mTc-pertechnetate may be being produced in vivo [Nemmar et al, 
2002]. Whilst plausible there was no evidence of in vitro oxidation in either 
Nemmar’s or our own control studies.   
 
It is possible that differences in chromatography technique could explain this 
disparity. Nemmar et al dried the blood sample at the origin of the plate before 
running the chromatogram (Dr A Nemmar, personal communication), whilst we 
placed it immediately into the mobile phase. It is possible that a period of drying 
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would favour 99mTc retention at the origin. Interestingly, in our study there was a 
small but reproducible peak of activity at the origin in blood sampled 6 hours after 
inhalation. This may reflect particle bound activity due to translocation via a 
different mechanism involving a slower active transfer of particles from the lung into 
the circulation. Alternatively, the activity may be intracellular due to phagocytosis of 
particulate in the lung alveolar space or interstitium by cells of the 
monocyte/macrophage lineage, which then enter the circulation. Further studies are 
required to determine the significance of this finding. Thin layer chromatography is 
an indirect method of particle detection, and ideally, a more direct strategy could be 
employed to track particles in the bloodstream. Techniques such as electron 
microscopy would be limited by the small concentration of particles, difficulty 
resolving structures in the nanoparticulate range, and the low electron density of 
carbon.  
 
In the study by Nemmar et al, 10% of the initial lung radioactivity was present in the 
liver after 5 minutes, which the authors suggest is due to the accumulation of 
circulating particles in the Kupffer cells. If most of the circulating 99mTc were 
particle bound and cleared in this way then radioactivity should increase over time in 
the liver. However, it did not, but rather increased steadily in the bladder. It is 
possible that the large amount of activity measured over the liver was not associated 
with the liver and simply reflected scatter from the lung. An alternative explanation 
could relate to the vascularity of this organ. If there is a large quantity of circulating 
unbound 99mTc, either as Pertechnegas from a generator contaminated with oxygen 
or from oxidation in vivo, then radioactivity over highly vascular organs might well 
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be high. Furthermore, it would remain static, as hepatic blood flow is unlikely to 
change during the course of the study, or even decrease, as 99mTc-pertechnetate is 
filtered by the kidneys.  
 
In our study, the only discernable pattern of radioactivity across the abdomen, 
outwith the bladder, was suggestive of gastrointestinal uptake, which is likely to be 
due to either mucociliary clearance of particles from the bronchial tree or swallowing 
of particles that had deposited in the mouth. The small quantities of radioactivity 
detected in the left and right upper quadrants likely reflect scatter from the lung or 
overlap of the lung and liver parenchyma. This absence of appreciable radioactivity 
in the liver or spleen is consistent with previous animal [Kreyling et al, 2002] and 
human studies [Brown et al, 2002]. There were small amounts of activity in the 
thyroid and stomach at 60 and 360 minutes after inhalation, both glandular organs in 
which 99mTc-pertechnetate is known to localise.  
 
The ability of nanoparticles to cross the lung-blood barrier is likely to be influenced 
by particle size. Differences in size of the primary particle and in the degree of 
particle aggregation could potentially explain the differences between study results. 
In our aerosol the majority of particles were singlet and less than 10 nm in diameter, 
but these rapidly formed aggregates of approximately 100 nm in diameter in the 
inhaled aerosol. Nemmar and colleagues identified 5 nm particles, but the average 
particle size and the size distribution of aggregated particles in the inhaled aerosol 
was not reported. During our study, a standard protocol for generating and 
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administering Technegas was followed, making it unlikely that particles would 
aggregate to a greater or lesser extent than in previous studies. 
 
The escape of nanoparticulate from the lung into the bloodstream has been advanced 
as a mechanism for the adverse cardiovascular effects of air pollution, whilst 
‘engineered’ nanoparticles in the nanotechnology industry could pose the same risks 
[Donaldson et al, 2004]. The fact that Technegas nanoparticles do not translocate 
directly into the blood in this study does not necessarily mean that other 
nanoparticles behave similarly, nor does it rule out an interaction between inhaled 
particulate and the vasculature. Environmental combustion derived nanoparticulate, 
as a carrier of soluble organic compounds from unburned hydrocarbon fuels [Levsen, 
2002], and oxidized transition metals [Sydbom et al, 2001], may well exert an 
important influence on the cardiovascular system. 
 
In conclusion, our results suggest that small quantities of soluble 99mTc species, not 
99mTc-radiolabelled nanoparticles, are responsible for the increase in radioactivity 
found in the bloodstream following Technegas inhalation. Robust chromatography 
and clear radio-nuclear imaging provide support for this statement. The low 
pulmonary retention rates of 99mTc and whole body images reported in Nemmar et al 
are suggestive of a high degree of Pertechnegas contamination. However, thin layer 
chromatographic analysis of their aerosol, blood and urine are not entirely consistent 
with this, and in light of our findings are difficult to explain. A better knowledge of 
the toxicokinetics of nanoparticulate is required before we can make general 
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6.1 SUMMARY 
Exposure to traffic-derived air pollution is associated with adverse cardiovascular 
events. The mechanisms for this association are unknown. We conducted a 
controlled exposure to dilute diesel exhaust in patients with stable coronary heart 
disease to determine the direct effect of air pollution on myocardial, vascular and 
fibrinolytic function. In a double blind randomized cross-over study, 20 men with 
prior myocardial infarction were exposed to dilute diesel exhaust (300µg/m3) or 
filtered air for one hour during periods of rest and moderate exercise in a controlled 
exposure facility. During the exposure, myocardial ischemia was quantified by ST-
segment analysis using continuous 12-lead electrocardiography. Six hours following 
exposure, vascular vasomotor and fibrinolytic function were assessed by means of 
intra-arterial agonist infusions. During both exposures, heart rate increased with 
exercise (P<0.001 for both) to a similar extent (P=0.67; diesel exhaust versus filtered 
air). Exercise induced ST-segment depression was present in all patients but there 
was a greater increase in ischemic burden during exposure to diesel exhaust (-22±4 
versus -8±6mVs, P<0.001). Exposure to diesel exhaust did not aggravate pre-existing 
vasomotor dysfunction, but did reduce acute endothelial tissue plasminogen activator 
release (P<0.05; area under the curve decreased by 35%). Brief exposure to dilute 
diesel exhaust promotes myocardial ischemia and inhibits endogenous fibrinolytic 
capacity in men with stable coronary heart disease. Our findings have identified 
ischemic and thrombotic mechanisms that may explain in part the observations that 
exposure to combustion-derived air pollution is associated with adverse 




The WHO estimates that air pollution is responsible for 800,000 premature deaths 
worldwide each year [World Health, 2004]. Short-term exposure to air pollution has 
been associated with increases in cardiovascular morbidity and mortality with deaths 
due to ischemia, arrhythmia and heart failure [Brook et al, 2004]. Miller et al 
recently reported that long-term exposure to air pollution increases the risk of death 
from cardiovascular disease by 76% [Miller et al, 2007]. These associations are 
strongest for PM2.5, of which combustion-derived nanoparticulate in diesel exhaust is 
an important component [Laden et al, 2000]. Significant improvements in air quality 
have occurred over the last 50 years, yet the association between PM2.5 and mortality 
has no apparent threshold and is evident below current air quality standards [Ware, 
2000]. 
 
Pre-clinical models of exposure to particulate air pollution demonstrate accelerated 
atherosclerotic plaque development [Sun et al, 2005a] and increased in vitro 
[Radomski et al, 2005] and in vivo [Nemmar et al, 2004] platelet aggregation. 
Epidemiologic and observational clinical studies suggest that exposure to air 
pollution may worsen symptoms of angina, [von Klot et al, 2005] exacerbate 
exercise induced myocardial ischemia [Gold et al, 2005; Pekkanen et al, 2002], and 
trigger acute myocardial infarction [Peters et al, 2001a; Peters et al, 2004]. These 
clinical findings are limited by imprecision in the measurement of pollution 
exposure, the effect of potential confounding environmental and social factors, and 
the lack of mechanistic data [Stone, 2004]. Controlled exposures of air pollutants can 
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help to address these shortcomings by providing a precisely defined exposure in a 
regulated environment that facilitates investigation with validated biomarkers and 
surrogate measures of cardiovascular health. Using a carefully characterised 
exposure system, we have previously shown in healthy volunteers that exposure to 
dilute diesel exhaust causes lung inflammation [Salvi et al, 1999], depletion of 
airway antioxidant defences, [Behndig et al, 2006] and impairment of vascular and 
fibrinolytic function [Mills et al, 2005].To date, there have been no controlled 
exposures in patients with coronary heart disease: an important population who may 
be particularly susceptible to the adverse cardiovascular effects of air pollution. 
 
We have therefore assessed the effect of dilute diesel exhaust inhalation on 
myocardial, vascular and fibrinolytic function in an “at risk” population of patients 




6.3.1 Subjects  
Twenty patients with stable coronary artery disease participated in this study that was 
performed with the approval of the local research ethics committee, in accordance 
with the Declaration of Helsinki, and with the written informed consent of all 
volunteers.  
 
All patients had proven coronary heart disease with a previous myocardial infarction 
(>6 months previously) treated by primary angioplasty and stenting, and were 
receiving standard secondary preventative therapy. Patients with angina pectoris 
(Canadian Cardiovascular Society grade 2), a history of arrhythmia, diabetes 
mellitus, uncontrolled hypertension, renal or hepatic failure, or those with unstable 
coronary disease (acute coronary syndrome or unstable symptoms within 3 months) 
were excluded. All volunteers were invited to a pre-study screening visit for exercise 
stress testing and patients unable to achieve stage 2 of the Bruce protocol, or patients 
who had marked ECG changes (left bundle branch block, early ST depression 
>2mm) or developed hypotension were excluded. Current smokers and those with 
asthma, significant occupational exposure to air pollution, or an inter-current illness 
were also excluded from the study.  
 
6.3.2 Study design 
Using a randomized double blind cross-over study design, volunteers attended at 
08.00 hours on two occasions at least two weeks apart for controlled exposure to 
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dilute diesel exhaust or filtered air. Each subject was exposed for one hour in an 
exposure chamber as previously described [Salvi et al, 1999]. During each exposure, 
subjects performed two 15-min periods of exercise on a bicycle ergometer separated 
by two 15-min periods of rest. For each subject, the ergometer workload was titrated 
to achieve a minute ventilation of 15 L/min/m2 to ensure a similar exposure. The 
workload was constant for both exposures and was equivalent to Stage 2 of the Bruce 
Protocol (range 110-150 Watts, 5-7 METS). All volunteers were fitted with 12-lead 
Holter electrocardiographic monitors (Reynolds Medical Lifecard 12, Delmar 
Reynolds, UK). Based on previous exposure studies in healthy volunteers, vascular 
assessments were performed 6-8 hours following diesel or air exposure [Mills et al, 
2005].  
 
6.3.3  Diesel Exposure  
The diesel exhaust was generated from an idling Volvo diesel engine (Volvo TD45, 
4.5L, 4 cylinders, 680rpm) from Swedish Low Sulphur Gasoil E10 (Preem, 
Göteborg, Sweden) as described previously [Salvi et al, 1999]. Over 90% of the 
exhaust was shunted away, and the remainder diluted with filtered air heated to 20oC 
(humidity ~50%) before being fed into a whole body exposure chamber (3x3x2.4m) 
at a steady-state concentration.  
 
The chamber was continuously monitored for pollutants with exposures standardised 
using NOx concentrations to deliver a PM concentration of 300µg/m
3 (median 
diameter 54nm; range 20-120). There was little variation in particle number 
(1.26±0.01x106 particles/cm3), NOx (4.45±0.02ppm), NO2 (1.01±0.01ppm), NO 
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(3.45±0.03ppm), CO (2.9±0.1ppm) and total hydrocarbon (2.8±0.1ppm) 
concentrations between exposures. The predominant PAH (~90%) were 
phenanthrene, fluorene, 2-methylfluorene, dibenzothiophene and different methyl-
substituted phenanthrenes. Only a minor fraction of PAH (3.5%) was associated with 
PM: 0.04% total PM and 0.06% PM organic fraction. PM10 and NO2 concentrations 
in the exposure chamber were 6- and 10-fold greater than WHO air quality standards 
of 50µg/m3 and 0.105ppm respectively [World Health Organisation, 2000]. 
 
6.3.4 Vascular studies 
All subjects underwent brachial artery cannulation with a 27-standard wire gauge 
steel needle. Following a 30min baseline saline infusion, acetylcholine at 5, 10 and 
20µg/min (endothelium-dependent vasodilator; Clinalfa AG, Switzerland), 
bradykinin at 100, 300 and 1000pmol/min (endothelium-dependent vasodilator that 
releases tissue plasminogen activator; Clinalfa AG) and sodium nitroprusside at 2, 4 
and 8µg/min (endothelium-independent vasodilator; David Bull Laboratories, UK) 
were infused for 6min at each dose. The three vasodilators were separated by 20min 
saline infusions and given in a randomised order. ACE inhibitor therapy was 
withdrawn 7 days prior to each vascular study as it augments bradykinin induced 
endothelial t-PA release [Witherow et al, 2002]. All other medications were 
continued throughout the study.  
 
Forearm blood flow was measured in both arms by venous occlusion 
plethysmography using mercury-in-silastic strain gauges as described previously 
[Newby et al, 1999]. Supine heart rate and blood pressure in the non-infused arm 
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were monitored at intervals throughout each study using a semi-automated non-
invasive oscillometric sphygmomanometer. 
 
6.3.5 Fibrinolytic and Inflammatory Markers 
Blood (10mL) was withdrawn into acidified buffered citrate (Stabilyte tubes, 
Biopool International) for t-PA assays, and citrate (BD Vacutainer) for PAI-1 assays. 
Plasma t-PA and PAI-1 antigen concentrations were determined by enzyme linked 
immunosorbant assays (TintElize t-PA, Biopool EIA; Coaliza PAI-1, Chromogenix 
AB). Serum CRP concentrations were measured using an immunonephelometric 
assay (Behring BN II nephelometer, Marburg, Germany). 
 
6.3.6 Data analysis and statistics 
Electrocardiographic recordings were analysed using the Reynolds Medical 
Pathfinder Digital 700 Series Analysis System (Delmar Reynolds, United Kingdom). 
ST-segment deviation was calculated by comparing the ST-segment during each 15-
min exercise test with the average ST-segment for the 15-min immediately prior to 
the start of the exposure. The ST-segment amplitude was determined at the J-point 
plus 80ms. The ischemic burden during each exercise test was determined as the 
product of the change in ST-segment amplitude and the duration of exercise. Leads 
II, V2, and V5 were selected a priori for ST-segment analysis to reflect separate 
regions of myocardium. Maximum ST-depression and ischaemic burden were 
determined for these leads individually and as a composite.  
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Plethysmographic data and net t-PA release were determined as described previously 
[Newby et al, 1997]. Continuous variables are reported as mean±SEM. Statistical 
analyses were performed with GraphPad Prism (Graph Pad Software, USA) using 
ANOVA with repeated measures and two-tailed Student’s t-test where appropriate. 
Statistical significance was taken at a two-sided P<0.05. All authors were involved in 





Subjects were all middle-aged males with predominantly single vessel coronary 
artery disease (Table 6.1). They reported no symptoms of angina and had no major 
arrhythmias during, or in the 24 hours following, exposure.  
 
Table 6.1  Baseline characteristics of patients with coronary heart disease (n=20) 
Age (years) 60 ± 1 
Cigarette smokers (Non-/Ex-/Current) 12/8/0 
Hypertension 8 
Height (cm) 173 ± 6 
Weight (kg) 79 ± 3 
Body mass index (m2/kg) 27 ± 1 
Time since index infarction, months 35±4 
Coronary angiogram  









Lipid profile  
Total cholesterol (mg/dL) 173 ± 6 
LDL-cholesterol (mg/dL) 100 ± 8 
HDL-cholesterol (mg/dL) 48 ± 2 
Triglycerides (mg/dL) 128 ± 23 





ACE inhibitor*/ARB 4 
 
Values are presented as number or mean ± SEM; 
LAD=left anterior descending artery; 
RCA=right coronary artery; 
LDL=low density lipoprotein; 
HDL=high density lipoprotein; 
ACE=Angiotensin converting enzyme; 
ARB=angiotensin receptor blocker 
*ACE inhibitor therapy was withdrawn 7 days prior to each vascular study. All other regular 
medications were continued throughout the study. 
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6.4.1  Myocardial Ischemia 
Heart rate increased with exercise during diesel exhaust and filtered air exposures 
respectively (P<0.001, for both versus baseline; P=0.67, diesel exhaust versus 
filtered air exposure; Table 6.2). Myocardial ischemia was detected during exercise 
in all patients with greater maximum ST-segment depression during exposure to 
diesel exhaust than filtered air (Table 6.2, Figure 6.1A and B, P<0.05). The ischemic 
burden induced by exercise was greater during exposure to diesel exhaust (Figure 
6.1C, P<0.001).  
 
Table 6.2 Effect of exercise on heart rate and ST-segment during filtered air and 
diesel exhaust exposures 
 Air Diesel P value 







Baseline HR, bpm 63 ± 2 61 ± 2 0.24 
Maximum HR, bpm 87 ± 3 86 ± 3 0.67 
Maximum ST , µV    
Lead II -28 ± 13 -56 ± 10 0.03 
Lead V2 -28 ± 10 -41 ± 12 0.18 
Lead V5 -14 ±8 -33 ± 9 0.04 
Ischemic burden, mVs    
Lead II -11 ± 5 -23 ± 4 0.004 
Lead V2 -13 ± 5 -21 ± 6 0.04 
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Lead V5 -4 ± 3 -12 ± 4 0.01 







Baseline HR, bpm 67 ± 2 65 ± 2 0.35 
Maximum HR, bpm 91 ± 3 87 ± 3 0.12 
Maximum ST , µV    
Lead II -17 ± 15 -49 ± 12 0.006 
Lead V2 -18 ±12 -41 ±13 0.04 
Lead V5 -7 ± 9 -28 ± 10 0.02 
Ischemic burden, mVs    
Lead II -8 ± 6 -22 ± 4 0.0007 
Lead V2 -11 ± 5 -20 ± 6 0.02 
Lead V5 -2 ± 3 -12 ± 5 0.006 
Values are mean ± SEM;  



























Figure 6.1 Myocardial ischemia during 15-min of exercise stress (period 1: +15 to 
+30 min) whilst exposed to diesel exhaust (red) or filtered air (blue). (A) Average 
change in heart rate and ST-segment in lead II. (B) Maximal ST-segment depression 
(P=0.003, diesel exhaust versus filtered air), and (C) total ischemic burden (P<0.001, 
diesel exhaust versus filtered air) as an average of leads II, V2, and V5 (n=20). 
 
 
6.4.2 Vasomotor Function 
There were no differences in resting heart rate, blood pressure or baseline non-
infused forearm blood flow between or during the two study visits. Although there 
was a dose-dependent increase in blood flow with each vasodilator (P<0.001 for all), 
neither endothelium-dependent nor independent vasodilation was affected by 
inhalation of diesel exhaust (Figure 6.2). Comparison with a contemporary reference 
population of healthy male volunteers (age 53±4 years), demonstrated impaired 
vasodilatation to acetylcholine but not sodium nitroprusside-induced vasodilatation 














Figure 6.2 Infused (solid line) and non-infused (dashed line) forearm blood flow in 
patients 6-8 hours following diesel exposure (red) and filtered air (blue), and a 
reference matched healthy control population (green) during intra-brachial infusion 
of acetylcholine and sodium nitroprusside (SNP). For all dose responses in the 
infused arm, P<0.0001. For diesel exposure versus air, P=0.54 for acetylcholine and 
P=0.56 for sodium nitroprusside (n=17). For patients versus healthy controls, P<0.05 
for acetylcholine and P=0.72 for sodium nitroprusside.  






































6.4.3 Fibrinolytic and Inflammatory Markers 
There were no differences in basal plasma concentrations of t-PA (10.5±1.0 versus 
9.5±1.0ng/mL) or its endogenous inhibitor, PAI-1 (18.8±3.0 versus 17.0±2.0ng/mL), 
six hours following either exposure. Likewise leukocyte, neutrophil and platelet 
count, and serum CRP concentrations were not altered at 6 or 24 hours by diesel or 
air exposure. Bradykinin caused a dose-dependent increase in plasma t-PA 
concentrations (data not shown) and net t-PA release (Figure 6.3) in the infused arm 
(P<0.001 for both) that was suppressed (P<0.05, area under the curve decreased by 










































































Figure 6.3 In comparison to filtered air (blue), diesel exhaust inhalation (red) 
reduced net t-PA release (product of forearm plasma flow and the concentration 
difference between the two arms) by 35% (P<0.05, diesel exhaust versus filtered air) 




We have demonstrated that transient exposure to dilute diesel exhaust, at 
concentrations occurring in urban road traffic, exacerbates exercise-induced 
myocardial ischemia and impairs endogenous fibrinolytic capacity in men with 
coronary heart disease. These findings provide a plausible explanation for the 
epidemiologic observations that exposure to air pollution is associated with adverse 
cardiovascular events. 
 
Particulate matter concentrations can regularly reach levels of 300g/m3 in heavy 
traffic, occupational settings, and in the world’s largest cities [Report, 1994]. A 
major proportion of this mass is attributable to combustion-derived nanoparticles 
from traffic; ranging from 20% at remote monitoring sites [Lanki et al, 2006] up to 
70% in a road tunnel [Geller et al, 2005]. Exposure to 300g/m3 for one hour 
increases a person’s average exposure over a 24-hour period by only 12g/m3. 
Changes of this magnitude occur on a daily basis even in the least polluted cities, and 
are associated with increases in cardiorespiratory mortality [Samet et al, 2000]. Our 
model is therefore highly relevant both in the composition and magnitude of 
exposure for the assessment of short-term health effects in man.  
 
Given potential safety concerns, we recruited patients who had stable and 
symptomatically well-controlled coronary heart disease with good exercise tolerance 
on formal stress testing. Volunteers were closely monitored throughout the exposure 
and reported no adverse effects. Despite similar changes in heart rate, we 
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documented asymptomatic myocardial ischemia that was increased up to three-fold 
by diesel exhaust inhalation. This reproducible effect was present despite a high use 
of maintenance ß-blocker therapy in patients without limiting angina. Thus we have 
established an immediate pro-ischemic effect of diesel exhaust inhalation, and we 
believe this provides an important mechanism for the observed increase in 
myocardial infarction in the hour following exposure to traffic [Peters et al, 2004]. 
 
Small areas of denudation and thrombus deposition are a common finding on the 
surface of atheromatous plaques and are usually sub-clinical. Rosenberg and Aird 
have postulated that vascular bed-specific defects in hemostasis exist, and that 
propagation of coronary thrombosis is critically dependent upon the local fibrinolytic 
balance [Rosenberg and Aird, 1999]. The efficacy of endogenous fibrinolysis is 
determined by the local release of t-PA from the vascular endothelium. The 
magnitude and rapidity of t-PA release regulates the generation of plasmin and 
therefore determines the effective removal of intravascular thrombus.  
 
We have previously reported impaired acute t-PA release 6 hours following diesel 
exhaust inhalation in healthy volunteers although this effect was not seen at an 
earlier (2 hours after exposure) time point [Mills et al, 2005]. We have now 
confirmed similar reductions in acute t-PA release 6 hours after diesel exhaust 
inhalation in patients with coronary heart disease. This delayed effect on endogenous 
fibrinolysis cannot explain our findings of immediate myocardial ischaemia but is 
consistent with the observations of Peters and colleagues who reported a second peak 
in the incidence of myocardial infarction 5-6 hours after traffic exposure [Peters et 
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al, 2004]. Pre-clinical thrombotic models also lend support to our findings. In a 
hamster model, Nemmar and colleagues have reported that instillation of diesel 
exhaust particulate into the lungs increases venous and arterial thrombus formation at 
sites of vascular injury [Nemmar et al, 2003a]. Taken together, these findings 
indicate an important thrombotic effect of diesel exhaust inhalation that may promote 
coronary thrombosis. 
 
Although we found important adverse effects of diesel exhaust on vascular 
fibrinolytic function, we did not demonstrate an effect on vasomotor function. 
However, it is important to appreciate that vasomotor function was assessed 6 hours 
after exposure and 5 hours after we documented an increase in ischemic burden. We 
have previously demonstrated that exposure to diesel exhaust impairs vasomotor 
function in healthy volunteers [Mills et al, 2005]. This effect was most marked at 2 
hours but was still present 6 hours after exposure. We cannot therefore exclude a 
detrimental vasomotor effect in patients at an earlier time point.  
 
Patients with coronary heart disease have impaired endothelial function [Zeiher et al, 
1991], and we have confirmed the presence of endothelial dysfunction in our study. 
This may have hindered our ability to demonstrate a further impairment of vascular 
function following diesel exhaust exposure. In addition, we performed our 
assessments in the presence of concomitant medications that are known to influence 
endothelial vasomotor function [Treasure et al, 1995]. Furthermore, Brook and 
colleagues have reported no effect of air pollution on endothelium-dependent 
vasodilatation [Brook et al, 2002]. 
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We have identified two distinct and potentially synergistic adverse cardiovascular 
effects of air pollution in patients with coronary heart disease. These effects provide 
plausible mechanisms that may contribute to the increased incidence of myocardial 
infarction following exposure to traffic. However, the precise mechanisms whereby 
diesel exhaust inhalation induces these ischemic and thrombotic effects have not 
been established in our study and will need to be addressed in future work.  
 
Our findings are consistent with recent epidemiological studies that report 
associations between ambient particulate air pollution and increased myocardial 
ischaemia on formal exercise testing [Gold et al, 2005; Pekkanen et al, 2002]. 
Myocardial ischaemia occurs as a consequence of reduced myocardial oxygen supply 
or increased demand or both. We hypothesize that oxidative stress and microvascular 
dysfunction in the resistance vessels of the myocardium may, in part, explain the 
adverse ischemic effects of exposure to dilute diesel exhaust. In vitro studies, animal 
models and human exposures have clearly established the oxidant and pro-
inflammatory nature of combustion-derived particulate matter [Donaldson et al, 
2003]. Indeed, the pattern of vascular dysfunction in our previous studies suggested a 
role for oxidative stress and reduced nitric oxide availability in mediating the adverse 
vascular effects of diesel exhaust inhalation [Mills et al, 2005]. 
 
Diesel exhaust is a complex mixture of gases and particles, and from our findings we 
cannot exclude a non-particulate cause of these adverse cardiovascular effects. 
However, in epidemiologic studies [Brunekreef and Holgate, 2002], particulate 
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matter has been held responsible for the majority of the adverse health effects of air 
pollution [Schwartz, 1994]. This view is supported by the recent observations of 
Miller et al in which they report a strong association between long-term exposure to 
particulate matter and cardiovascular outcome but no association with gaseous 
pollutants [Miller et al, 2007]. Ambient nitrogen dioxide can be considered a 
surrogate for traffic derived pollution, but has little adverse effect in controlled 
chamber studies even at the exposure levels seen here [Blomberg, 1997]. We 
therefore suggest that the cardiovascular effects described here are mediated 
primarily by diesel exhaust particulate and not its other components. This argues for 
the use of diesel exhaust particle traps to limit the adverse health impact of traffic 
emissions. However, the causative association of particulates must first be 
definitively established and the efficacy of particle traps confirmed. 
 
Brief exposure to dilute diesel exhaust increases myocardial ischemia and impairs 
endogenous fibrinolytic capacity in men with stable coronary heart disease. Our 
findings suggest pathophysiologic mechanisms for the observation that exposure to 
combustion-derived air pollution is associated with adverse cardiovascular events 
including acute myocardial infarction. Environmental health policy interventions 
targeting reductions in urban air pollution should be considered in order to decrease 
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Exposure to fine particulate air pollution is associated with increased cardiovascular 
morbidity and mortality. We previously demonstrate that exposure to combustion-
derived particulate from an idling diesel engine causes vascular dysfunction in man. 
In this study we wish to determine whether exposure to increased concentrations of 
‘real world’ ambient particulate matter causes vascular dysfunction. Twelve male 
patients with stable coronary heart disease and 12 age-matched volunteers were 
exposed to fine + ultrafine CAPs or filtered air for 2 hours using a randomized 
double-blinded cross over study design. Bilateral forearm blood flow, fibrinolytic 
and inflammatory variables were measured 6-8 hours after CAPs or filtered air in 
response to intra-brachial agonist infusions. Particulate concentrations in the 
exposure chamber were higher than ambient levels and filtered air (190±37 vs 31±8 
vs 0.5±0.4 g/m3; P<0.001). Chemical analysis of CAPs identified low levels of 
elemental carbon. Exhaled breath 8-isoprostane concentrations increased after 
exposure to CAPs (16.9±8.5 pg/ml vs 4.9±1.2 pg/ml, P<0.05) but markers of 
systemic inflammation were largely unchanged. Although there was a dose 
dependent increase in blood flow with each vasodilator and plasma t-PA release 
(P<0.001), this was unaffected by CAPs in either group. Despite achieving marked 
increases in particulate concentration, exposure to CAPs did not affect vasomotor or 
fibrinolytic function in either middle aged healthy volunteers or patients with 
coronary heart disease. Exposure to particulate air pollution low in combustion 





Epidemiological and clinical research accumulated over 50 years has established the 
adverse effects of air pollution on human health. The London smog of December 
1952 caused more than 4,000 excess deaths [Ministry of Health, 1954], and despite 
the dramatic decreases in levels of air pollution that have been achieved since then, 
the association between air pollution and cardiorespiratory morbidity and mortality 
persists [Anderson et al, 1996; Dockery et al, 1993; Pope et al, 2002]. These 
associations are strongest for PM2.5 and the majority of excess deaths are due to 
cardiovascular events [Pope, 2000]. Despite the strength of the epidemiological 
evidence and the emergence of promising hypotheses, the constituents and biological 
mechanisms responsible for the cardiovascular effects of air pollution are only 
beginning to emerge.  
 
Exposure to particulate air pollution has been associated with exercise-induced 
myocardial ischaemia in patients with coronary heart disease [Pekkanen et al, 2002] 
and the triggering of acute myocardial infarction [Peters et al, 2001a]. These findings 
are limited by exposure misclassification, the effect of potential confounding 
environmental and social factors, and the lack of mechanistic data [Stone, 2004]. 
Controlled exposures of air pollutants can help to address these shortcomings by 
providing a precisely defined exposure in a regulated environment that facilitates 
investigation with validated biomarkers and surrogate measures of cardiovascular 
health. 
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Using a carefully characterised exposure system, we have previously shown that 
exposure to dilute diesel exhaust causes lung inflammation [Salvi et al, 1999], 
depletion of airway antioxidant defences [Behndig et al, 2006], and impairment of 
vascular and fibrinolytic function [Mills et al, 2005]. Whilst controlled exposure to 
diesel exhaust is an excellent model for studying the effects of pure combustion-
derived air pollution we acknowledge that ambient air pollution contains a range of 
particulate pollutants from a variety of atmospheric sources. In the last few years, 
technology has been developed that can deliver a continuous flow of air in which the 
concentration of ambient particulate is increased in real-time [Sioutas et al, 1997, 
Sioutas et al, 1995]. The principle advantage of these concentrators is that they 
provide ‘real-world’ inhalation exposures under controlled conditions.  
 
In previous studies, exposure to fine concentrated ambient particulate (CAPs) 
induced mild pulmonary inflammation in healthy adults [Ghio et al, 2000], and 
altered  heart rate variability in the elderly [Devlin et al, 2003] and in asthmatic and 
healthy younger adults [Gong et al, 2003].  Furthermore, exposure to CAPs plus 
ozone causes peripheral arterial vasoconstriction [Brook et al, 2002] and an increase 
in arterial pressure [Urch et al, 2005]. To date no studies have addressed the effects 
of exposure to CAPs in isolation on vascular function, nor have any previous studies 
assessed the effect of these exposure in an ‘at risk’ population of patients with 
established coronary heart disease. We therefore assess the effects of a two hour 
exposure to fine + ultrafine CAPs on vascular function, fibrinolysis and 





7.3.1 Subjects  
Twelve male patients with stable coronary heart disease and 12 age-matched male 
non-smoking volunteers participated in these studies, which were performed with the 
approval of the local research ethics committee, in accordance with the Declaration 
of Helsinki, and the written informed consent of all volunteers.  
 
All patients had proven coronary heart disease with a previous myocardial infarction 
or stable angina treated by angioplasty and stenting (>6 months prior to enrolment), 
and were receiving standard secondary preventative therapy (Table 7.1). Patients 
with angina pectoris (Canadian Cardiovascular Society grade 2), a history of 
arrhythmia, diabetes mellitus, uncontrolled hypertension, renal or hepatic failure, or 
those with unstable coronary disease (acute coronary syndrome or unstable 
symptoms within 3 months) were excluded. Matched control subjects were not 
taking regular medication and had no clinical evidence of atherosclerotic vascular 
disease, diabetes mellitus, hypertension, renal or hepatic failure.  
 
In both groups, current smokers and those with asthma, significant occupational 
exposure to air pollution, or an inter-current illness were excluded from the study. 
All subjects had normal lung function and none of them reported symptoms of 




7.3.2 Study design 
Subjects attended on two occasions two weeks apart and received fine + ultrafine 
CAPs or filtered air in a randomised double-blind cross-over design. Each subject 
was exposed for two hours in a specially built whole body exposure chamber. During 
each exposure subjects performed moderate exercise (minute ventilation 25 
L/min/m2) on a bicycle ergometer that was alternated with rest at 15 minute intervals.  
 
Based on previous exposure [Mills et al, 2005] and systemic inflammatory [Salvi et 
al, 1999] studies, vascular assessments were performed 6-8 hours following CAPs or 
filtered air exposure. All subjects abstained from alcohol for 24 hours and from food, 
tobacco and caffeine-containing drinks for at least 4 hours before each vascular 
study. Studies were carried out in a quiet, temperature controlled room maintained at 
22-24ºC with subjects lying supine. All subjects remained indoors between the 
exposure and vascular assessment to minimise additional exposure to particulate air 
pollution.  
 
7.3.3 Concentrated ambient particle exposures and characterisation 
A Versatile Aerosol Concentration Enrichment System (VACES) concentrator [Kim 
et al, 2000], within a Mobile Ambient Particle Concentrator Exposure Laboratory 
(MAPCEL) was used to deliver exposures to concentrated fine + ultrafine particles 
(CAPs, diameter <2.5 µm) and filtered air. The CAPs were derived from an urban 
background site outside the Royal Infirmary Edinburgh (Ordnance Survey Grid 
Reference, NT 289 703) approximately 6 miles from the centre of Edinburgh in 
Scotland, United Kingdom. A bus route passed adjacent to the MAPCEL and an 
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arterial city-route was located a few hundred meters away. 
 
The air in the exposure chamber was continuously monitored for temperature, 
humidity, NOx, CO, SO2, and ozone. Particle number was determined using a 
condensation particle counter. Particle mass was continuously monitored using a 
DataRam nephelometer to standardise diesel exposures, with the precise mass 
determined by gravimetric filter measurements. The concentration of CAPs was not 
standardised for all subjects, as exposures were dependent on ambient particulate 
levels on the day of the study. We aimed to deliver approximately 200 µg/m3 to 
allow comparison with previously published studies [Mills et al, 2005]. 
 
An Aerosol Time-Of-Flight Mass Spectrometer (ATOFMS) was employed to 
characterise the single particulate matter sampled during the CAPS exposures. The 
operation of ATOFMS instrument has been described in detail elsewhere [Toner et 
al, 2006] and detailed results are presented elsewhere [Freney et al, 2006]. 
 
7.3.4 Vascular studies 
All subjects underwent brachial artery cannulation with a 27-gauge steel needle 
under controlled conditions. Following a 30 min baseline saline infusion, 
acetylcholine at 5, 10 and 20 µg/min (endothelium-dependent vasodilator that does 
not release t-PA; Merck Biosciences, Switzerland), bradykinin at 100, 300 and 1000 
pmol/min (endothelium-dependent vasodilator that releases t-PA; Merck 
Biosciences, Switzerland) and sodium nitroprusside at 2, 4 and 8 µg/min 
(endothelium-independent vasodilator that does not release t-PA; David Bull 
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Laboratories, UK) were infused for 6 min at each dose. The three vasodilators were 
separated by 20 min saline infusions and given in a randomised order. Forearm blood 
flow was measured in the infused and non-infused arms by venous occlusion 
plethysmography using mercury-in-silastic strain gauges. Supine heart rate and blood 
pressure in the non-infused arm were monitored at intervals throughout each study 
using a semi-automated non-invasive oscillometric sphygmomanometer. 
 
7.3.5 Fibrinolytic and Inflammatory Markers 
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the ante-
cubital fossae of both arms. Blood (10 mL) was withdrawn simultaneously from each 
arm at baseline and during the infusion of each dose of bradykinin, and collected into 
acidified buffered citrate (Stabilyte tubes, Biopool International) for t-PA assays, and 
citrate (BD Vacutainer) for PAI-1 assays. Samples were kept on ice before being 
centrifuged at 2000 g for 30 minutes at 4°C. Platelet-free plasma was decanted and 
stored at -80°C before assay. Plasma t-PA and PAI-1 antigen concentrations were 
determined by enzyme linked immunosorbant assays (TintElize t-PA, Biopool EIA; 
Coaliza PAI-1, Chromogenix AB). Haematocrit was determined by capillary tube 
centrifugation at baseline and during infusion of bradykinin 1000 pmol/min.  
 
Blood samples were taken immediately before, 6 and 24 hours after the exposure and 
analysed for total cells, differential count and platelets using an autoanalyzer. Serum 
CRP concentrations were measured using an immunonephelometric assay (Behring 
BN II nephelometer, Marburg, Germany). 
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7.3.6  Exhaled breath condensate 
In a pilot study exhaled breath condensate (EBC) was collected using a Jaeger 
Ecoscreen (VIASYS Healthcare, Hoechberg, Germany) immediately before, 6 and 
24 hours after exposures in 8 healthy volunteers. Subjects rinsed their mouths with 
water immediately prior to the collection. EBC was collected during a 10-minute 
period of normal tidal breathing through the mouthpiece with a nose clip in place. 
Samples were placed on ice immediately after collection and aliquoted for storage at 
-80˚C within 30 minutes. 8-isoprostane and nitrotyrosine were measured in EBC 
using commercially available enzyme-linked immunosorbent assays (Quantikine, 
R&D Systems, Minneapolis). 
 
7.3.7 Data analysis and statistics 
Plethysmographic data were analysed as described previously [Newby et al, 1999]. 
Estimated net release of t-PA antigen was defined as the product of the infused 
forearm plasma flow (based on the mean haematocrit and the infused forearm blood 
flow) and the concentration difference between the infused and non-infused arms 
[Newby et al, 1997]. Continuous variables are reported as mean ± SEM. Statistical 
analyses were performed with GraphPad Prism (Graph Pad Software) using ANOVA 
with repeated measures, Pearson’s correlation, and two-tailed Student’s t-test where 
appropriate. The area under the curve was calculated for the estimated net release of 




Subjects tolerated the exposures well and did not report any symptoms during or in 
the 24-hours after each exposure. Patients and controls were well matched for age 
and blood pressure (Table 7.1), and all patients were on optimal medication for 
secondary prevention. Patients with coronary artery disease were shorter and more 
overweight with greater BMI than the healthy controls (P<0.05).   
 
Table 7.1  Baseline characteristics of coronary heart disease patients and controls 
 Controls Patients Significance 
Age (years) 54±2 59±2 0.12 
Height (cm) 181±1 176±2 0.03 
Weight (kg) 81±3 87±3 0.14 
Body mass index (m2/kg) 25±1 28±1 0.02 
FEV1 (L) 3.4±0.1 3.0±0.2 0.04 
FVC (L) 4.6±0.2 4.2±0.2 0.07 
Ratio 74±1 72±2 0.32 
Systolic blood pressure (mmHg) 135±5 138±6 0.69 
Diastolic blood pressure (mmHg) 77±3 80±3 0.50 
Heart rate (bpm) 63±3 54±1 0.006 
Previous MI 0 7  
Previous PTCA 0 7  
Previous CABG 0 1  
Current-smokers  0 0  
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Ex-smokers (Non-/Ex-/Current) 3 5  
Non-smokers (Non-/Ex-/Current) 9 7  
Hypertension 0 4  
Hypercholesterolaemia 0 12  
Drugs    
Aspirin 0 12  
Statin 0 12  
	-blocker 0 11  
ACE inhibitor*/ARB 0 7  
Values are presented as number or mean ± SEM or number; 
FEV= forced expiratory volume in 1 second; 
FVC= forced vital capacity; 
MI = myocardial infarction; 
PTCA = percutaneous transluminal coronary arteriography; 
CABG = coronary artery bypass grafting;  
ACE = angiotensin converting enzyme; 
ARB = angiotensin receptor blocker 
*ACE inhibitor therapy was withdrawn 7 days prior to each vascular study. All other regular 
medications were continued throughout the study. 
 163 
7.4.1   Exposures to ambient particles  
Ambient particulate concentrations were variable (Range 3-174 g/m3) during the 
three month duration of the study with an average concentration of 20±4 g/m3. 
Particulate concentrations in the exposure chamber were higher than ambient levels 
and filtered air (190±37 vs 31±8 vs 0.5±0.4 g/m3; P<0.001). There were no 
significant differences between concentrations of gaseous co-pollutants between the 
filtered air or CAPs exposures (Table 7.2). There were however differences in 
humidity and temperature in the chamber between the CAPs and filtered air 
exposures that occurred as a result of the saturation and dilution phases of the 
enrichment process.  
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Table 7.2  Exposure variables 
 Air CAPs Significance 
PM [Teflon filter] (µg/m3) - 178±46 <0.001 
PM [Quartz filter] (µg/m3) - 162±22 <0.001 
PM [Data Ram] (µg/m3) 0.5±0.4 190±37 <0.001 
Ambient PM [Data Ram] (µg/m3) 9±1 31±8 0.01 
Particle no. (1,000 x number/cm3) - 99.4±9.5 <0.001 
Ozone (ppb) 6.0±1.3 5.0±1.2 0.52 
Carbon monoxide (ppb) 27±1 24±3 0.40 
Sulphur dioxide (ppb) 0.13±0.07 0.13±0.07 1.00 
Nitric oxide [NO] (ppb)  4.5±0.3 4.6±1.0 0.93 
Nitrogen dioxide [NO2] (ppb) 5.9±0.7 5.1±1.0 0.52 
NOx [NO +NO2] (ppb) 6.3±0.7 7.2±1.7 0.60 
Temperature (oC) 21.1±0.2 20.1±0.2 0.004 
Relative humidity (%) 28±2 57±2 <0.001 
Values are presented as number or mean ± SEM (n=24) 
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Using the ATOFMS, elemental analysis of ambient particulate was acquired during 
each two-hour exposure for a representative two-week period of the study. The 
ATOFMS detected low levels of carbon (5.3±1.2% of all analysed particles), and 
















Figure 7.1 ATOFMS analysis of ambient particulate during each two-hour exposure 
in a representative two-week period. The ATOFMS detected low levels of carbon, 
and sodium chloride as the primary chemical constituent of ambient aerosol. 
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Vascular function 
There were no differences in resting heart rate, blood pressure or baseline forearm 
blood flow following exposure to CAPs or air in either cohort (Table 7.3). 
Bradykinin, acetylcholine, and sodium nitroprusside caused dose-dependent 
increases in forearm blood flow following both air and CAPs exposure (P<0.0001), 
however this increase in blood flow was not affected by exposure to CAPs or filtered 
air in either patients or controls (Figure 7.2). Bradykinin caused a dose-dependent 
increase in plasma t-PA antigen concentrations (P<0.0001) that was similarly 
unaffected by exposure (Table 7.4). We found no correlation between peak forearm 
blood flow and particle mass or particle number in the CAPs exposure for any of the 
vasodilators infused. 
 
Table 7.3  Haemodynamics variables 6 hours following exposure in all subjects 
   Air CAPs Significance 
Heart rate (bpm) 58±2 58±1 0.94 
Systolic blood pressure (mmHg) 135±4 135±4 0.51 
Diastolic blood pressure (mmHg) 78±2 78±2 0.96 
Mean arterial pressure (mmHg) 97±2 97±3 0.70 
Infused FBF (mL/100 mL tissue/min) 2.6±0.3 2.5±0.2 0.57 
Non-infused FBF (mL/100 mL tissue/min) 2.7±0.2 2.3±0.2 0.16 



































































































































































































































































































































































































































































































































































































































































































































































































Markers of oxidative stress and inflammation 
Exhaled breath condensate levels of 8-isoprostane increased 6- and 24-hours after 
CAPs exposure compared to filtered air (ANOVA, P=0.04; Figure 7.3) where as 
levels of nitrotyrosine did not significantly differ between exposures. In all subjects 
there was a small increase in the number of circulating platelets (234±8 vs. 
225±8x109/L, P=0.007 at 2-hours) and monocytes (0.58±0.03 vs. 0.53±0.03 x109/L, 
P=0.03 at 6-hours) following exposure to CAPs versus filtered air (Table 7.5). There 
was however no clear evidence of a systemic inflammatory response to CAPs 
exposure with total leucocyte, neutrophil, and lymphocyte counts or serum CRP 











Figure 7.3 In health volunteers (n=8) exhaled breath condensate levels of 8-


















































































































































































































































































































































































































































































































































































































































































































































































Exposure to concentrated ambient particulate for two hours in a typical urban 
environment did not affect vascular vasomotor or endogenous fibrinolytic function in 
either middle-aged healthy volunteers or patients with coronary heart disease. 
Edinburgh ambient particulate was generally low in elemental carbon indicating that 
combustion sources were not a major source of ambient particulate. Inhalation of 
CAPs caused mild pulmonary oxidative stress, but did not result in a significant 
systemic inflammatory response. Exposure to particulate air pollution low in 
combustion component, even at concentrations 5-fold higher than the United States 
Environmental Protection Agency (EPA) National Ambient Air Quality Standards 
(NAAQS), is unlikely to cause significant adverse vascular effects capable of 
triggering an acute coronary events.  
 
These findings contrast those from our previous studies in which we report 
impairments of vascular function in both healthy volunteers patients with coronary 
heart disease following a one hour exposure to dilute diesel exhaust [Mills et al, 
2005; Törnqvist et al, 2007]. This apparent discrepancy requires further discussion 
with differences in particle number, particle composition, and the presence of 
gaseous co-pollutants between these exposures potentially responsible. 
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7.5.1  Ambient particle and diesel exhaust exposures 
We were able to increase the concentration of ambient particulate 6- to 8-fold to 
deliver exposures of between 50 and 682 µg/m3. The majority of exposures were 
substantially higher than the USEPA standard of 65 µg/m3 for daily PM2.5. Exposure 
to 190 µg/m3 for 2 hours is roughly comparable to a one-hour exposure to the 300 
µg/m3 of diesel exhaust particulate delivered in previous studies. We are confident 
that these on-line estimates of exposure are accurate as the precise mass determined 
by gravimetric filter measurements. It is possible that vascular dysfunction only 
occurred in subjects exposed to the highest concentrations of CAPs and that a 
significant overall effect of exposure to CAPs on vascular function was masked by 
those volunteers receiving only modest particle exposures. This seems unlikely given 
we found no relationship between particle number or mass and vasodilatation to any 
of the endothelial-dependent or –independent agonists infused. 
 
Whilst we delivered a similar mass of particulate in our present study and previous 
exposures to diesel exhaust, there were important differences in particle size and 
therefore particle number concentration between the exposures. In dilute diesel 
exhaust the particulate consists of pure combustion-derived carbon nanoparticulate. 
These particles typically range from 20 to 120 nm, with a count median diameter of 
54 nm (geometric standard deviation = 1.7 nm) [Mills et al. 2007]. The mean particle 
size in a typical CAPs exposure was 1.2±0.4 µm in diameter. The total number of 
suspended particles in dilute diesel exhaust was therefore 10-fold more than in the 
CAPs exposure. Toxicological studies have determined that the adverse oxidative 
and pro-inflammatory effects of particles are in part determined by surface area 
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[Duffin et al, 2007]. It follows that smaller particles exert a greater effect per unit 
mass than larger particles of similar toxicity. It is therefore possible that the lack of 
adverse vascular effects following exposure to CAPs reflects the relatively low 
number concentration of particles in the present study. 
 
Diesel exhaust is a complex mixture of gases and particles, and whilst we 
hypothesise that our previous findings are principally due to an effect of combustion-
derived particles, it is not possible to definitively exclude a non-particulate cause of 
the adverse vascular effects. Potentially important co-pollutants produced in the 
combustion of diesel oil include nitrogen oxides and carbon monoxide. One of the 
advantages of the VACES system is that it allows us to study the effects of 
particulates alone and the enrichment process does not alter the concentration of 
gaseous pollutants. Concentrations of NO2 and CO were low and easily within the 
recommended EPA’s NAAQS in our present study. Whilst in epidemiological 
studies ambient NO2 or CO have been primarily considered surrogates for traffic 
derived pollution [Brunekreef and Holgate, 2002], it is possible that these gaseous 
pollutants in diesel exhaust exert a synergistic effect with the particulates. There are 
no previous studies addressing the effects of NO2 or CO in isolation on the vascular 
or fibrinolytic systems, however controlled chamber studies suggest that NO2 even at 
the exposure levels seen here does not cause significant lung inflammation 
[Blomberg et al, 1997]. 
 
As an important source of combustion-derived particulate, diesel exhaust is strongly 
implicated in the observed adverse effects of air pollution. A variable proportion of 
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urban PM is attributable to combustion-derived nanoparticles from traffic; ranging 
from 20% at remote monitoring sites [Lanki et al, 2006] up to 70% in a road tunnel 
[Geller et al, 2005]. In Edinburgh CAPs, only 5.3% of particles analysed contained 
elemental carbon and the principle constituent was pure, mixed or reacted sea-salts 
(91.7±6.5 %). This is not surprising given Edinburgh’s maritime climate. Air-mass 
source attribution plots for the 5 days prior to arrival at the sampling location were 
calculated for each of the exposure periods using a United Kingdom Met Office 
model [Manning AJ, 2003]. In all cases air clearly originated either predominantly 
from the Atlantic or the Arctic with very little contribution from air passing over land 
apart from final arrival over central Scotland [Freney et al, 2006]. The proportion of 
airborne particulate derived from remote combustion sources is likely to be low. It is 
very likely that the absence of any detrimental vascular effects in the present study in 
part reflect the composition of Edinburgh CAPs, which is likely to be very low 
toxicity. 
 
7.5.2 Air pollution, oxidative stress and inflammation 
A substantial body of evidence supports a role for oxidative stress in determining the 
toxicity of ambient pollution [Donaldson et al, 2005a] and in the pro-inflammatory 
effects of combustion-derived particles [Donaldson et al, 2005b; Nemmar et al, 
2003b]. Reactive oxidant species arise not only from the redox potential of the 
pollutants themselves, but also from the activation of alveolar epithelial cells or 
resident macrophage and the recruitment of circulating neutrophils. In our study we 
used an emerging non-invasive method of assessing pulmonary oxidative stress 
through collection of exhaled breath condensate [Montuschi et al, 1999]. In these 
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preliminary studies we found an increase in exhaled breath 8-isoprostane suggesting 
that inhaled ambient particles exert a pro-oxidant effect in the airways. This is the 
first time to our knowledge this technique has been used to assess the effects of 
exposure to air pollutants and if these findings can be replicated and extended in a 
larger study breath condensate measures may become a useful biomarker of PM 
exposure. 
 
In panel and population studies PM exposure is associated with evidence of an acute 
phase response with increased CRP [Peters et al, 2001b] and plasma fibrinogen 
[Pekkanen et al, 2000; Schwartz, 2001], enhanced plasma viscosity [Peters et al, 
1997] and altered haematological indices [Seaton et al, 1999]. In animal studies there 
are similar reports with increased fibrinogen in the blood of PM-exposed 
hypertensive rats [Cassee et al, 2002] and normal rats exposed to ultrafine carbon 
particles [Elder et al, 2004b]. We did not find a consistent systemic inflammatory 
signal with no change in the number of circulating neutrophils, lymphocytes, or total 
leucocytes even up to 24 hours following CAPs exposure. Similarly we did not find 
an increase in serum CRP concentrations suggesting that a 2-hour exposure to CAPs 
is not sufficient to cause a sustained systemic inflammatory response.  
 
The number of circulating platelets increased 2 hours following CAPs exposure and 
a similar transient effect on circulating monocytes was present at 6 hours. Whether 
these small changes are likely to increase cardiovascular risk is questionable. Whilst 
the cellular mechanisms of atherosclerosis are complex, adhesion of platelets and 
monocytes to the damaged arterial wall occurs early in response to vascular injury 
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[Fuster et al, 1992]. Activated platelets deposit at sites of plaque rupture and may 
precipitate coronary artery occlusion. Platelet-monocyte aggregates are increased in 
cigarette smokers [Harding et al, 2004] and patients with unstable angina [Sarma et 
al, 2002] suggesting that leukocyte–platelet interactions may contribute to 
atheromatous plaque instability. Whilst we have not measured markers of platelet or 
monocyte activation in our study, it has recently been reported that inhalation of 
carbon ultrafine particles alters leukocyte expression of adhesion molecules in 
peripheral blood [Frampton et al, 2006]. 
 
7.5.3  Study limitations 
Using a robust randomised double blind sham-exposure study design we have 
assessed the effect of CAPs on two complementary aspects of vascular function. 
Impaired vasodilatation and fibrinolytic function in the forearm vascular bed have 
previously been shown to independently predict adverse outcomes in patients with 
coronary heart disease [Heitzer et al, 2001; Robinson et al, 2007] and therefore we 
believe this model is a reasonable surrogate for cardiovascular health. Furthermore, 
these studies were conducted in a highly relevant population of patients with existing 
coronary heart disease who are likely to be susceptible to the adverse effects of air 
pollution and for whom a better understanding of the effects of exposure to 
particulate air pollution is of clinical importance. The findings are clear; a two-hour 
exposure to increased concentrations of ambient particulate in an urban setting does 
not have significant effects on systemic vascular function.  
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However, it is not possible to generalise our findings or state that in other urban 
settings exposure to PM is not likely to exert harmful vascular effects. This is 
primarily because the maritime climate and location of the MAPCEL resulted in an 
exposure to low levels of combustion component. The concentrator technology relies 
on environmental conditions on the study date to ensure that a relevant exposure can 
be delivered, and therefore we were not able to give a pre-specified concentration of 
ambient particulate. Whilst we delivered almost 200 µg/m3 it is possible that higher 
concentrations even of low toxicity CAPs would have had a more potent adverse 
effects. Further studies in different cities and city locations are clearly warranted. 
 
Conclusions 
Despite achieving substantial increases in ambient particulate concentrations in an 
urban setting exposure to ambient particulate air pollution for two hours had no 
effect on vascular vasomotor or endogenous fibrinolytic function in either healthy 
middle-aged volunteers or patients with established coronary heart disease. These 
findings suggest that exposure to particulate matter that is low in combustion 
component is unlikely to exert significant vascular effects capable of triggering an 








CONCLUSIONS AND FUTURE DIRECTIONS 
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8.1 SUMMARY OF THESIS FINDINGS 
 
Short and long-term exposure to air pollution is associated with increases in 
cardiovascular morbidity and mortality with deaths due to ischaemia, arrhythmia and 
heart failure [Brook et al., 2004]. These associations are strongest for fine particulate 
air pollutants, of which combustion-derived particulate in diesel exhaust is an 
important component. Whilst the mechanisms responsible for these associations are 
only partly understood, observational studies suggest that exposure to air pollution 
may worsen symptoms of angina, exacerbate exercise induced myocardial ischemia, 
and trigger acute myocardial infarction [Peters et al., 2006]. These clinical findings 
are limited by imprecision in the measurement of pollution exposure, the effect of 
potential confounding environmental and social factors, and the lack of mechanistic 
data. Controlled exposures of air pollutants can help to address these shortcomings 
by providing a precisely defined exposure in a regulated environment that facilitates 
investigation with validated biomarkers and surrogate measures of cardiovascular 
health.  
 
In health the vascular endothelium delicately balances regulatory pathways 
controlling blood flow, coagulation, fibrinolysis and inflammation. It is widely 
recognized that a variety of risk factors including cigarette smoking can influence 
vascular tone through endothelium-dependent actions, and there is now extensive 
evidence of abnormal endothelium-dependent vasomotion in patients with 
atherosclerosis [Newby et al., 1999 and 2001]. As combustion products and 
particulate matter are common to both air pollution and cigarette smoke, we 
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hypothesised that air pollution is likely to have similar detrimental effects on 
vascular function. 
 
8.1.1 Diesel exhaust inhalation causes vascular dysfunction and impaired 
endogenous fibrinolysis 
 
In a double-blind randomised crossover study, 30 healthy men were exposed to 
dilute diesel exhaust (300 µg/m3 particulate concentration) or air for one hour during 
intermittent exercise. Using a powerful study design, we have assessed two 
important and complementary aspects of vascular function: the regulation of vascular 
tone and endogenous fibrinolysis. Both are impaired and plausibly related to the 
well-documented cardiovascular effects of air pollution [Mills et al., 2005].  
 
8.1.2 Persistent endothelial dysfunction after diesel exhaust inhalation 
In our subsequent studies we demonstrate that endothelial dysfunction persists 24-
hours following exposure and is associated with an increase in systemic 
inflammatory cytokines [Törnqvist et al., 2007]. These changes in vascular function 
are less marked than seen at the earlier time points and the time-course of this 
vascular effect of exposure is more in keeping with enhanced oxidative stress. In 
support of this we demonstrate using electron paramagnetic resonance studies that 
diesel exhaust particles are capable of generating reactive oxidative species, and that 
this effect can be quenched by superoxide dismutase.  
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8.1.3 Do inhaled carbon nanoparticles translocate directly into the circulation 
in man? 
Whether inhaled nanoparticles can cause vascular oxidative stress directly through 
translocation from the lungs into the circulation requires further study [Mills et al., 
2006]. In an attempt to extend the findings from the only previously published 
clinical study to address whether inhaled nanoparticles translocate we identify 
serious flaws in the original study. It seems likely that small quantities of inhaled 
particulate can reach the systemic circulation, however it is more plausible that the 
acute vascular effects are mediated by a soluble factor or a pro-inflammatory or 
oxidised protein released from the lungs. 
 
8.1.4 Ischemic and thrombotic effects of dilute diesel exhaust inhalation in men 
with coronary heart disease 
Recently the AHA published a scientific statement in which, on the strength of the 
observational studies, they advise patients to restrict physical activity on days in 
which air pollution levels are increased [Brook et al., 2004]. Perhaps a surprisingly 
strong statement given there have been no controlled exposures to air pollutants in 
patients with coronary heart disease. Whilst the recent COMEAP report to the UK 
Department of Health acknowledges the role of air pollution in the pathogenesis of 
cardiovascular disease the authors of this report did not feel that there was sufficient 
evidence to support avoidance strategies. 
 
Patients with coronary artery disease are an important population who may be 
particularly susceptible to the adverse cardiovascular effects of air pollution. We 
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have therefore assessed the effect of dilute diesel exhaust inhalation on myocardial, 
vascular and fibrinolytic function in an “at risk” population of patients with stable 
coronary heart disease.  Twenty patients with prior myocardial infarction were 
exposed to dilute diesel exhaust (300 µg/m3) or filtered air during periods of rest and 
moderate exercise in a controlled exposure facility. During the exposure, myocardial 
ischemia was quantified by ST-segment analysis using continuous 12-lead 
electrocardiography. Exercise induced ST-segment depression was present in all 
patients but there was a 3-fold greater increase in ST segment depression and 
ischemic burden during exposure to diesel exhaust. Exposure to diesel exhaust did 
not aggravate pre-existing vasomotor dysfunction, but did reduce acute endothelial t-
PA release. We have demonstrated that transient exposure to dilute diesel exhaust, at 
concentrations occurring in urban road traffic, exacerbates exercise-induced 
myocardial ischemia and impairs endogenous fibrinolytic capacity in patients with 
coronary heart disease [Mills et al., 2007].  
 
8.1.5 Exposure to concentrated ambient particles does not affect vascular 
function in men with coronary heart disease 
Finally we extend our studies to address whether concentrated real world particles 
exert similar detrimental effects on vascular function in both healthy volunteers and 
patients with coronary heart disease. These studies were conducted outside the Royal 
Infirmary in Edinburgh. Despite achieving a 10-fold increase in ambient fine 
particulate concentrations we did not find that a 2-hour exposure to Edinburgh 
ambient particulate caused any detrimental effects on either vasomotor or 
endogenous fibrinolytic function in patients or control subjects. The component of 
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ambient particulate arising from combustion processes was exceedingly low and we 
conclude that particle composition is critical in determining the adverse vascular 
effects of PM air pollution. 
 
 
8.2 FUTURE DIRECTIONS 
 
A number of questions have arisen from the results and peer review of the above 
studies that we hope to explore in future studies. There are several highly relevant 
clinical and environmental health issues that need to be addressed. 
 
8.2.1 Are combustion-derived nanoparticles responsible for the adverse 
vascular effects of diesel exhaust?   
Diesel exhaust is a complex mixture of gases, particles and volatiles, and our earlier 
studies preclude identification of the component(s) responsible for the adverse 
effects. Nitrogen dioxide, carbon monoxide, ozone, metals and organics (unburnt 
fuel and lube oil), and formaldehyde may play a role. We propose to identify the 
precise component of diesel exhaust that mediates the adverse cardiovascular effects 
using combinations of carbon particle generators, particle filtration, and pure gaseous 
exposures. This is an important consideration in the science of emission control 
technology, where the focus is on reducing the most important emission to gain a 
health advantage. A focused regulatory approach with the reduction of specific 
pollutants is likely to be the most cost effective approach to improving public heath 
[Ware et al, 2000].  
 184 
 
To address this question we will recruit sixteen healthy non-smoking volunteers who 
will attend on four occasions, more than two weeks apart, and receive dilute diesel 
exhaust (300 µg/m3), filtered diesel exhaust (gaseous pollutants only), filtered air or 
ultrafine carbon particle exposures in a double-blind randomised cross-over fashion. 
They will perform moderate exercise or rest alternated at 15-minute intervals while 
sitting on a recumbent bicycle ergometer during each two-hour exposure. Forearm 
vascular responses and inflammatory markers will be determined 6-8 hours after the 
completion of each exposure.  
 
All subjects will be exposed in the MAPCEL with modifications to allow controlled 
exposures to diesel exhaust, filtered diesel exhaust and carbon particles (Figure 8.1). 
The diesel exhaust will be generated from an unloaded diesel engine (Deutz, 4 
cylinder, 2.2 L, 500 rpm) using standard commercially available gas oil (Petroplus 
Refining Teesside Ltd., United Kingdom). High efficiency particle filtration will be 
achieved by passing the dilute diesel exhaust through an impactor with a cutoff of 
0.1µm and a TE38 Teflon filter (Schleicher & Schuell, Dassel, Germany). Ultrafine 
‘pure’ carbon particles will be generated from graphite electrodes in an electric spark 




Figure 8.1 Diesel exhaust will be generated from an unloaded diesel engine using 
gas oil. More than 90% of the exhaust will be shunted away, and the remaining part 
diluted with air and fed at 75 L/min into the exposure chamber at steady-state 
concentration. Diesel exhaust particulate will be removed for the control filtered 
exhaust exposure by passing dilute exhaust through a Teflon filter. Carbon 




8.2.2  Are the adverse vascular effects of diesel exhaust related to the 
magnitude of exposure?  
Particulate matter concentrations can regularly reach levels of 300 µg/m3 in heavy 
traffic, occupational settings, and in the world’s largest cities [WHO, 1994]. A major 
proportion of this mass is attributable to combustion-derived nanoparticles from 
traffic; ranging from 20% at remote monitoring sites [Lanki et al, 2006] up to 70% in 
a road tunnel [Geller et al, 2005]. Exposure to 300 µg/m3 for one hour increases a 
person’s average exposure over a 24-hour period by only 12 µg/m3. Changes of this 
magnitude occur on a daily basis, and are associated with increases in 
cardiorespiratory mortality [Dockery et al, 1993]. However, we recognise that many 
people may not be exposed to this level of air pollution. We therefore need to explore 
the dose-response relationship of these effects and determine if a threshold exists.  
 
Sixteen non-smoking volunteers with normal lung function and no history of 
respiratory disease will be invited to attend on four separate days at least two weeks 
apart and receive a double-blind randomised cross-over exposure to filtered clean air 
or diesel exhaust at 30, 100 and 300 µg/m3. Vascular function will be determined 6-8 
hours following the end of each exposure using venous occlusion plethysmography. 
 
8.2.3 Does diesel exhaust inhalation reduces exercise capacity and increase 
ischaemic burden in patients with stable angina pectoris?   
We have undertaken the first controlled diesel exhaust exposures in patients with 
coronary heart disease. Given potential safety concerns, we recruited stable 
asymptomatic patients who had been revascularized and had good exercise tolerance 
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on formal stress testing. Volunteers were closely monitored throughout the exposure 
and reported no adverse effects. Despite similar changes in heart rate, we 
documented painless myocardial ischaemia that was increased up to three-fold by 
diesel exhaust inhalation. This reproducible effect was present despite a high use of 
maintenance ß-blocker therapy in patients without limiting angina. It seems likely 
that diesel exhaust inhalation will have greater impact in other patient populations, 
such as those with limiting angina. We therefore need to explore whether diesel 
exhaust inhalation has functional consequences including reduced exercise capacity 
in patients with stable angina pectoris. We also need to explore whether diesel 
exhaust inhalation has other cardiovascular consequences in such patients. 
 
Twenty patients with stable angina pectoris will attend on four occasions at least two 
weeks apart. All subjects will have a 12-lead Holter monitor for the 24 hours during 
and following exposure. Subjects will be exposed to filtered air, 30, 100 and 300 
µg/m3. Exercise tolerance testing will be performed according to the Bruce protocol 
2 hours following the start of each exposure, with the time to symptom onset and 
time to 1mm ST-segment depression recorded. Blood samples will be immediately 
before and after the exposure and the stress test, and at 24 hours to measure markers 
of systemic inflammation and myocardial ischaemia including high sensitive 
troponin, ischaemically modified albumin, fatty acid binding protein and NT-brain 
natriuretic peptide. 
. 
We anticipate that there will be a dose response relationship between diesel exhaust 
inhalation and its pro-ischaemic effects. Measures of surrogate inflammatory, 
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ischaemic and cardiac markers will be used to determine the presence of adverse 
biochemical markers of myocardial ischaemia or injury. This will help determine the 
safe thresholds of diesel exhaust inhalation in patients with coronary heart disease. 
 
8.2.4 Development of fibrinolytic and thrombotic models 
We intend to explore whether the potential thrombogenic effects of air pollution can 
be further delineated using the Badimon chamber (BHF Project Grant PG/04/131; Dr 
Andrew Lucking). In brief, the Badimon chamber provides a powerful and elegant 
method of assessing ex vivo thrombus formation in an extracorporeal flow chamber 
[Badimon et al, 1999]. The technique utilises a continuous flow of venous effluent 
blood from the human forearm that is passed into a series of chambers containing a 
thrombogenic surface usually consisting of denuded porcine aortic strips. The 
characteristics of the flow chamber can be modified to generate low and high shear 
stress conditions that generate fibrin or platelet rich thrombi respectively. This 
powerful technique permits the dynamic formation of thrombus to be observed and 
allows the assessment of thrombotic and anti-thrombotic interventions. Combining 
the forearm model and Badimon chamber provides a unique opportunity to examine 
not only dynamic clot dissolution with endogenous t-PA release, but also to assess 
the prothrombotic effects of air pollution. 
 
8.2.5 Assessment of new technologies 
New strategies are currently in development to reduce diesel exhaust emissions, such 
as the introduction of new cleaner diesel fuels with ultra low sulphur content, and the 
retrofit of oxidation catalysts and particle filters. In the United States, the EPA is 
 189 
subsidising a voluntary programme to retrofit particle traps on commercial and 
public heavy-duty diesel engines as part of the National Clean Diesel Campaign 
(http://www.epa.gov/otaq/diesel/index.htm). Whilst particle filtration technology can 
reduce emissions there are uncertainties about the regeneration of these filters and 
therefore their long-term efficacy. To date there have been no studies that address the 
potential for reducing particle emissions from diesel engines to prevent the adverse 
health effects of exposure to diesel exhaust. 
 
Assessing the potential for new technologies to reduce emissions and prevent 
adverse cardiovascular effects will by necessity involve collaboration with industry. 
Through Professor Thomas Sandstrom at Umeå University we have access to a 
commercially available retrofit particle trap manufactured by Volvo (Gothenburg, 
Sweden). In future studies we will assess the efficacy of this particle trap and hope to 
conduct controlled exposures to diesel exhaust with and without particle filtration in 
both healthy volunteers and patients with coronary artery disease. These studies will 
determine the potential for commercially available technology to prevent the adverse 
vascular and pro-ischaemic effects of exposure to combustion-derived air pollution. 
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8.3  CLINICAL PERSPECTIVE 
 
Using a unique exposure system we have demonstrated that healthy volunteers who 
inhale dilute diesel exhaust develop an impairment of two important, highly relevant 
and complementary aspects of vascular function: the regulation of vascular tone and 
endogenous fibrinolysis. We have extended these findings and have shown that brief 
exposure to dilute diesel exhaust promotes myocardial ischemia and inhibits 
endogenous fibrinolytic capacity in patients with stable asymptomatic coronary heart 
disease. Taken together our findings provide a plausible explanation for the 
epidemiologic observations that exposure to air pollution is associated with adverse 
cardiovascular events including acute myocardial infarction.  
 
We believe environmental health policy interventions targeting reductions in the 
combustion component of urban air pollution should be considered in order to 
decrease the risk of adverse cardiovascular events. In future studies we hope to 
determine the minimum concentration of diesel exhaust exposure necessary to 
invoke these effects and assess the effects of commercially available retrofit exhaust 
treatments on cardiopulmonary health. These proposed studies will help inform 
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